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Porcine circovirus 2 (PCV2) is a small single stranded DNA virus responsible for
a group of detrimental diseases referred to as Porcine Circovirus Associated Diseases
(PCVAD). Observed variation in incidence and severity of PCVAD between pigs
suggests a host genetic role in facilitating PCV2 pathogenesis. This study builds on prior
research by Engle et al. (2014), who performed a large-scale genome-wide association
study of 974 crossbred pigs experimentally infected with a PCV2b isolate and provided
evidence of a host genetic role in PCV2 viremia, immune response, and growth. Two
major Quantitative Trait Loci (QTL) were identified for viral load located on
chromosome 7 (SSC7) near the swine leukocyte antigen complex class II (SLAII) locus
and the proximal end of chromosome 12 (SSC12). The SNP with largest association,
ALGA0110477 (SSC12), explained 11.1% of the genetic variance and 7.4% of the
phenotypic variance for viral load.
Dissection of the SSC12 QTL region using gene annotation and both genomic and
RNA sequencing uncovered a novel missense polymorphism within SYNGR2
(p.Arg63Cys) that exhibited the largest association with PCV2 viremia and immune
response. In vitro gene silencing of SYNGR2 was performed on porcine kidney 15 cell
line (PK15) using siRNA designed against the SYNGR2 mRNA sequence. A substantial

	
  

	
  

	
  

	
  

	
  
decrease in SYNGR2 mRNA expression (82.2%) was achieved and corresponded with a
significant reduction in PCV2 titer beginning at 48 hours post infection (P<0.05)
compared to scramble siRNA and non-transfected control cells, indicating a role of
SYNGR2 in viral replication. The SYNGR2 p.Arg63Cys mutation is located within a
protein domain conserved across mammals and results in an amino acid substitution
(ArgàCys) unique to swine. The impact of SYNGR2 on PCV2 replication and location of
a non-conservative substitution within a key domain provides strong evidence that the
SYNGR2 p.63Cys variant underlies the observed genetic effect on viral load by
potentially interfering with SYNGR2 activity. These findings provide important insight
into the role of host genetics in PCV2 pathogenesis.

Key Words: PCV2, susceptibility, viremia, immune response, replication, siRNA,
synaptogyrin-2, SYNGR2
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History of PCV2
Today, Porcine Circovirus 2 (PCV2) is recognized as a key threat to swine
populations worldwide. However, its characterization as a distinct and disease causing
pathogen did not occur until many years after its suggested emergence in 1962 [1] . The
virus was first identified in 1974 as a contaminate of a porcine kidney cell line (ATCCCCL31) that caused no observable cytopathic effects [2, 3]. This contaminant was
initially believed to be a picornavirus-like virus, but upon further analysis was

determined to be a single-stranded DNA virus with a covalently closed-circular genome,
about 1.76kb in length [3, 4]. The composition and properties of this virus were different
from any known animal pathogen and specific antibodies were found in sera collected
exclusively from pigs, indicating they were the likely species of origin [4]. As a result,
the unique virus was given the name porcine circovirus (PCV) and has since been
assigned to the Circoviridae family [4, 5].
Initial experimental infection of pigs with the PK-15 PCV isolate induced no
signs of clinical disease or evidence of viral replication, however, PCV specific
antibodies were detected in blood samples collected from the infected pigs [6]. Another
experimental infection using colostrum-deprived pigs validated the lack of pathogenesis,
but was able to detect PCV antigen in tissues throughout the body indicating viral
replication [7]. PCV specific antibodies were also present in asymptomatic
conventionally raised Canadian pigs and wild boars from the Berlin region of Germany.
Thus, PCV was deemed a non-pathogenic virus common of all swine [2, 6, 7].
In 1991, a new disease emerged in a previously healthy herd of Canadian pigs
free of any major enteric and respiratory diseases [8, 9]. Clinical signs appeared in

	
  

	
  

	
  
affected piglets about 2-3 weeks post-weaning and included wasting, dyspnea, jaundice,
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and lymphoid depletion [10]. This disease soon became known as Post-Weaning
Multisystemic Wasting Syndrome (PMWS), with the first description of PMWS given in
1996 [10]. PMWS cases have since been documented worldwide in piglets 5-12 weeks of
age and are associated with increased rates of mortality [8]. Subsequent investigations
into the culprit behind PMWS uncovered a potential link between disease onset and a
novel type of PCV, overturning the precedent that PCV was strictly non-pathogenic.
In 1998, a virus similar in size and morphology to the PK-15 PCV isolate was
found in tissue samples collected from Californian and French pigs with clinical signs of
PMWS, but not in healthy controls [11]. The ability to detect PCV-like nucleic acid using
in situ hybridization with a PCV genomic probe indicated that this virus was genetically
similar to the PK-15 PCV isolate, however, a difference in reactivity to monoclonal
antibodies suggested that it possessed distinct antigenic properties [11]. Genomic
comparison revealed that the nucleotide sequence similarity was less than 80% between
isolates from PMWS affected pigs and the PK-15 PCV isolate [12, 13]. Based on these
findings, a proposal was made to break PCV into two groups with the new potentially
pathogenic form classified as Porcine Circovirus type 2 (PCV2) and the non-pathogenic
PK-15 isolate as Porcine Circovirus type 1 (PCV1) [12].
Although PCV2 was detected in archived tissue samples collected as early as
1962 from pigs of Northern Germany, PCV2-associated pathological changes and lesions
did not appear in samples until 1985 [1]. In fact, the ability to detect viral DNA in
samples between 1962 and 1984 was highly variable with an estimated prevalence of
about 2.5%. However, this estimate sky-rocketed to over 30% in samples from 1985 and
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onward, coinciding with the first incidents of associated lesions and reports of PMWS [1,
14]. Specifically, the prevalence of PCV2 within PMWS affected farms was found to be
much higher than in non-affected farms as well as in PMWS affected pigs compared to
non-affected pigs [15]. PCV2 has since been implicated in a variety of other diseases and
symptoms aside from PMWS, such as Porcine Respiratory Disease Complex (PRDC),
Porcine Dermatitis and Nephropathy Syndrome (PDNS), weight loss, reproductive
failure, and lymphoid depletion [16-19]. In 2006, these diseases became collectively
referred to as Porcine Circovirus Associated Diseases (PCVAD) [20].

Porcine Circovirus Associated Diseases
According to the American Association of Swine Veterinarians (AASV), PCVAD
may be subclinical or consist of one or more clinical manifestations including:
multisystemic disease with wasting, respiratory problems, PDNS, enteric conditions,
reproductive disorders, and high mortality that are present solely or combined in a group
of animals [20]. The Veterinary Diagnostic Laboratory at Iowa State University,
classifies systemic infection and PCV2-associated pneumonia, enteritis, reproductive
failure, and PDNS under PCVAD in the diagnostics database [20]. In an individual pig,
PCVAD is diagnosed by microscopic lesions with an abundance of PCV2 antigen.
Evaluation of intestine, lung, and lymphoid tissue for the presence of PCV2 antigen by
immunohistochemistry must be performed in order to determine specific PCVAD
manifestation [20].
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a) Subclinical PCV2 Infection

A diagnosis of subclinical PCV2 infection is characterized by low levels of PCV2 antigen
that are not responsible for any clinical disease. There may be no or minimal lesions, with
infection often limited to one or two lymph nodes [20].

b) Post-Weaning Multisystemic Wasting Syndrome (PMWS) and Systemic Infection
Systemic PCV2 infection is characterized by lymphohistiocytic or granulomatous
inflammatory lesions in lymphoid tissues, lung, intestines, liver, and/or heart [20]. The
first symptom is often weight loss, jaundice, or failure to thrive [20]. In order for PCV2
infection to be diagnosed as systemic, PCV2 antigen must be found in more than one
lymphoid tissue, one lymphoid tissue and one organ system, or two organ systems [17,
20]. If found in only one organ system than the diagnosis would be one of the other
PCVAD manifestations and not systemic infection [20]. PMWS falls within the realm of
systemic PCV2 infection. In order for a pig to be diagnosed with PMWS the following
requirements must be met: 1) wasting, weight loss, and failure to thrive with or without
labored breathing or jaundice, 2) histological lesions with lymphoid depletion or
granulomatous inflammation present within any organs, and 3) detection of PCV2
infection within these lesions [21, 22].

c) Porcine Respiratory Disease Complex (PRDC)
Respiratory disease cases that involve multiple pathogens are often characterized as
PRDC [16]. Characteristic symptoms of PRDC include decreased growth rate and feed
efficiency, anorexia, cough, labored breathing, and fever [20]. In 2000, over 3,000 cases

	
  

	
  

	
  
of swine pneumonia were diagnosed at the Iowa State University Veterinary Diagnostic
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Laboratory, with 694 cases classified as PCV2-associated pneumonia [16]. Of the 694
cases, 56% presented with concurrent Porcine Reproductive and Respiratory Syndrome
Virus (PRRSV) infection, 19% with Mycoplasma hyopneumoniae, and 12% with Swine
Influenza Virus (SIV) [16]. Three case studies, revealed that concurrent infection with
PCV2 and PRRSV, M. Hyopneumoniae, or SIV resulted in PRDC [16]. High levels of
PCV2 antigen found in lesions associated with granulomatous bronchointerstitial
pneumonia with bronchiolitis and bronchiolar fibrosis lend support for role of PCV2 in
prolonged respiratory disease [16, 20].

d) Porcine Dermatitis and Nephropathy Syndrome (PDNS)
Characteristic symptoms of PDNS include prominent raised purple skin lesions
commonly distributed on the hind legs, lethargy, and fever [20, 23]. Renal lesions are
also common and indicative of glomerulonephritis believed to be due accumulation of
antigen-antibody aggregates and immune complexes within specific tissues [20, 23].
PDNS is often fatal, with animals succumbing after only a short period of clinical disease
[23]. In a case control study, PCV2 was found in 100% of PDNS affected pigs
predominantly in the lymph nodes and tonsils [24]. Extremely high levels of PCV2
antibodies were consistently found in the serum of affected pigs and were significantly
higher compared to control pigs [24]. Accumulation of IgG and IgM antibodies as well as
complement factors and CD8+ cells were also found in the kidneys of affected animals,
indicating that excessive amounts of PCV2 antibodies caused by PCV2 infection may
induce PDNS [24].

	
  

	
  

7

	
  
e) PCV2-Associated Enteritis
Clinically, PCV2-associated enteritis mimics ileitis due to Lawsonia intracellularis
presenting with diarrhea, thickened intestinal mucosa, and enlarged mesenteric lymph
nodes [20]. Six weaned pigs were diagnosed with PCV2-associated enteritis using
histopathology, viral isolation, and in situ hybridization [25]. From this, the authors

propose that in order to diagnose PCV2-associated enteritis the following criteria must be
met: 1) presence of diarrhea, 2) typical lesions are found in Peyer’s patches, but not other
lymph nodes, and 3) PCV2 DNA or antigen must be detected within these lesions [25].

f) PCV2-Associated Reproductive Failure
Although rare amongst breeding populations, affected herds present with increased
number of abortions, stillbirths, mummifications, and preweaning mortalities [20, 26].
Field cases indicate that myocarditis is the most common lesion to be found in stillborn
or neonatal pigs along with elevated levels of PCV2 antigen [19]. Reproductive
abnormalities have also been induced through experimental intrauterine infection of
fetuses with PCV2, supporting the classification of PCV2 as a reproductive pathogen
[27].

Taxonomy, Characteristics, and Genomic Organization
PCV1 and PCV2 belong to the Circoviridae family and are classified under the
Circovirus genus. Members of the Circoviridae family are small, non-enveloped, singlestranded DNA viruses known to infect both pigs and birds [5, 28]. They have circular
genomes approximately 1.8 to 2.3kb in length with a common stem loop structure

	
  

	
  

	
  
containing the origin of replication (Ori) [20, 29, 30]. The genomic organization of
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circoviruses and their mechanisms of replication closely mirror those of plant
geminiviruses and nanoviruses [30]. In fact, further analysis of the Rep protein revealed a
substantial degree of similarity between the n-terminal regions in circoviruses and
nanoviruses [31]. However, the c-terminal region of the PCV Rep protein more closely
resembles an RNA binding protein of a vertebrate RNA calicivirus [31]. Therefore, it has
been proposed that PCV evolved after a recombination event between a nanovirus and
calicivirus.
There are currently 11 species of circoviruses including both types of PCV and
various avian circoviruses [30]. PCV1 and PCV2 are the smallest of the circovirus
species as well as among the smallest known viruses able to infect mammals and carry
out autonomous replication [30, 32, 33] . The PCV virion is composed of 60 capsid
protein subunits arranged in 12 pentamer clustered-units to form an icosahedron with T=1
symmetry that is 17±1.3nm in diameter [14, 30, 32]. The circular single-stranded DNA
genome packaged within these viral particles is approximately 1.7kb in length, encoding
only what is required for replication and infection [30].
Recently a new genotype of porcine circovirus, PCV3, was identified in pigs from
Missouri, Minnesota, and South Dakota with cardiac and multi-systemic inflammation
[34]. The strain was identified by metagenomic analysis. The Rep and Cap proteins of
PCV3 share the most homology, 55% and 35% respectively, with a circovirus found in
bat feces and less homology with PCV1 and PCV2, indicating PCV3 to be a novel
member of the Circovirus genus and the third found in pigs [34].
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Both PCV1 and PCV2 have 11 potential Open Reading Frames (ORFs), two of

which are necessary for viral replication and assembly [35]. ORF1 encodes the replicase
proteins, Rep and Rep’, and ORF2 encodes the capsid protein. The PCV genome is
considered ambisense because ORF1 and ORF2 are aligned in opposite directions, such
that ORF1 is oriented in the sense direction and ORF2 in the antisense direction relative
to the Ori [14, 30]. The Rep protein is encoded by the full ORF1 transcript (35.6 kDA),
while Rep’ results from an alternatively spliced ORF1 transcript (19.2 kDA) [29, 36].
Both proteins are required for replication in PCV1 and PCV2 with the capacity to
instigate replication at heterologous Ori [37]. The proteins differ slightly in size between
PCV1 and PCV2, however, four conserved sequence motifs were identified and deemed
crucial for Rep to initiate replication with any truncation or point mutation within a motif
leading to protein inactivation [36]. Three of these motifs are typical for proteins utilized
in rolling circle replication and the other contains the consensus sequence for a dNTPbinding box (GKS) [29, 36]. Additionally, an interferon-stimulated response element
(ISRE) was discovered in the Ori of the PCV2 genome that was shown to affect in vitro
interferon-mediated enhancement of PCV2 replication when present in an intact virus
[30, 38]. The capsid protein is approximately 30 kDA in size and identified as the
primary structural protein with the ability to self-assemble into capsid-like particles that
encapsulate the PCV genome [39].
There are two other ORFs that encode unique non-structural viral proteins not
involved in replication, but in other mechanisms of PCV2 infection. The ORF3 protein
differs significantly in size between PCV1 (23.2 kDA) and PCV2 (11.9 kDA), with only
about 62% sequence homology [35]. It is primarily found in the nucleus of infected cells,

	
  

	
  

	
  
peaking around 48 hours post infection and has been implicated in PCV2-induced
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apoptosis via activation of caspase-8 and caspase-3 pathways [40]. As a result, it is
believed to facilitate local viral spread by catalyzing early viral release from infected
cells as well as systemic dissemination by inducing macrophage phagocytosis of
apoptotic cells [41]. ORF4 completely overlaps ORF3 and encodes a 13.3 kDA protein in
PCV1 and a 6.5 kDA protein in PCV2, with 83% sequence homology [35]. It is believed
to counter virus-induced apoptosis by regulating expression of the ORF3 protein as well
as reduce viral replication via interactions with ORF1 mRNA during early stages of
infection [42]. In fact, cells infected with ORF4-deficient PCV2 mutants showed
increased ORF3 expression, caspase activity, and early viral growth [42].

Genetic Variation in PCV2 Strains
Although closely related, PCV2 shares only about 68-76% sequence similarity
with PCV1 [13, 14, 30]. A greater proportion of sequence discrepancies appear in ORF2
than ORF1 with nucleotide homologies of approximately 67% and 83% respectively [13].
As a result, the amino acid sequences of the ORF1 protein, Rep, is more conserved with
85% sequence homology between PCV1 and PCV2 while the Cap protein encoded by
ORF2 is more variable, sharing only about 65% similarity [13]. The overall nucleotide
sequence similarity between PCV2 isolates is significantly higher with 95% homology or
greater [12]. However, majority of differences once again occur within ORF2 with
approximately 90% nucleotide and amino acid homology across isolates [14]. Therefore,
it is believed that variation in the cap protein may contribute to differences in isolate
pathogenicity [43].
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PCV2 isolates cluster into distinct sub-groups or genotypes designated by lower

case letters [44], which are subsequently split into clades [45]. However, classification of
PCV2 isolates is not always clear cut due to genetic recombination between PCV2 strains
during coinfection, which has been illustrated in multiple studies to generate chimera
isolates resembling multiple sub-groups [46] and clades [47, 48]. Furthermore, novel
PCV2 strains continue to emerge at a rapid pace due to a high mutation rate [49]. In fact,
following the comparison of 160 PCV2 genomes, Firth et al. (2009) deduced that PCV2
has the highest nucleotide substitution rate of any ssDNA virus to date, reaching levels
more commonly achieved by RNA viruses [50].
Currently, PCV2 is divided into three subgroups denoted PCV2a, PCV2b, and
PCV2c, with PCV2a and PCV2b found worldwide. The existence of two more groups,
PCV2d and PCV2e, has been proposed based on isolates from China [51], however, the
methodology used in this study was determined insufficient to support classification as
separate sub-groups [52]. Analysis of archived samples dating back to the early 1980s
indicate that PCV2a precluded PCV2b in Northern Germany and the United Kingdom [1,
53] with similar reports corroborating this pattern in other countries, such as Denmark
[54] and China [51]. Although PCV2a and PCV2b were present in European countries
and China prior to 2003, phylogenetic analysis indicated a dramatic shift in
predominance towards the PCV2b sub-group at this time [14, 30]. Shortly after, PCV2b
also emerged in North America and Canada coinciding with increased incidences of
PCVAD [55, 56]. PCV2c was isolated from archived tissue samples between 1980-1990
from Danish pigs prior to PCVAD outbreaks in 2003 and 2004. Phylogenetic analysis
revealed a shift from PCV2c to PCV2a in the 1990s followed by another shift to PCV2b
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in the early 2000s [54]. Therefore, PCV2c may represent a precursor to both PCV2a and
PCV2b while PCV2b may represent the most adapted sub-group associated with
increased pathogenicity [14, 54].

PCV2 Transmission
The transportation of asymptomatic animals is believed to have enabled the rapid
dissemination of virulent PCV2 strains around the world as the geographic patterns of
PCV2 appearance mirror those of the global pig trade [49]. Transmission of PCV2 often
occurs via direct contact through oronasal, fecal, and urinary tracts [20]. In one study,
direct contact with pigs infected with PCV2 42 days prior resulted in transmission to
three out of three colostrum deprived control pigs [57]. Shedding patterns of PCV2 were
analyzed using PCR for detection of viral DNA in samples collected from 16 PCV2
experimentally infected pigs and 313 field cases [58]. The presence of PCV2 was
detected one day after inoculation in all oropharyngeal swabs, nasal swabs, and feces
samples and 7 days after inoculation in whole blood and serum samples obtained from
the experimentally infected pigs and remained positive for 70 days post infection for
most of the samples [58]. In field cases, detection of PCV2 DNA using PCR occurred in
30.4% of whole blood samples, 19.2% of nasal swabs, and 20.4% of fecal samples with
the frequency of positive samples increasing in post-weaning pigs approximately 3-4
months old [58]. Another study, including 146 pigs classified as either PMWS-affected,
PCV2 subclinically infected, or PCV2 negative, found that in general trachea-bronchial
swabs had the highest PCV2 load followed by serum, tonsillar, nasal, fecal, and urinary
swabs [59]. Different levels of PCV2 were detected between the three groups, with

	
  

	
  

	
  
PMWS affected animals exhibiting significantly higher proportions compared to the
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subclinically infected or negative groups [59]. Therefore, the authors conclude that PCV2
is excreted through respiratory and oral secretions as well as in feces and urine of both
PMWS affected and subclinically infected pigs [59].
Evidence of vertical PCV2 transmission has also been illustrated both
experimentally and in the field [20]. Specifically, transplacental transmission was shown
in cases of reproductive failure, late-term abortions, and stillbirths in which PCV2
antigen was detected in various tissues of dead piglets [19, 60]. Another study focused on
the ability of PCV2 to infect and its effects on late term fetuses [27]. Of the 37 fetuses
infected intramuscularly through the uterine wall between 86 and 93 days of gestation, 24
appeared phenotypically normal and 13 were unthrifty at farrowing, mummified, or
stillborn. PCV2 infection was detected in all 37 piglets, providing experimental evidence
that PCV2 can infect late term fetuses as well as induce reproductive abnormalities [27].
Additionally, intermittent shedding of PCV2 in semen of infected boars has been
illustrated by several studies [61-63] with PCV2 predominantly found within the seminal
fluid and non-sperm cell fraction [61]. Despite sporadic long term shedding in semen of
infected boars, no morphological or detrimental changes to sperm cells were observed in
the presence of PCV2 [63]. It is not known whether PCV2 in semen is infectious or
capable of transmission via artificial insemination, however, the potential threat this
poses to breeding programs worldwide is cause for concern.
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PCV2 Cellular Pathogenesis
The molecular mechanisms underlying PCV2 pathogenesis remain somewhat

elusive due to inconsistencies in PCV2 virulence that make it difficult to pinpoint exactly
how PCV2 elicits disease symptoms. However, pathogenesis is believed to begin with
PCV2 entry via oral and nasal cavities followed by viral replication in local lymphoid
tissues and subsequent systemic dissemination of the virus to other tissues and organs
[64]. Circulating PCV2 can be detected in sera by 7 days post infection (dpi), but peaks
between 14 and 21 dpi [9, 26, 65]. Widespread detection of PCV2 in a variety of tissues
and organs can be achieved beginning between 7 and 14 dpi, however, the highest viral
titers are most often found in lymphoid tissues [9, 66]. Lymphoid depletion is a defining
characteristic associated with PCV2 infection that causes reduced immune function and
increased susceptibility to secondary pathogens [10]. Thus, efficient primary infection of
lymphoid tissues may play an essential role in PCV2 induced immunosuppression and
overall pathogenesis.
PCV2 predominantly infects host epithelial, endothelial, and monocytic cells by
binding via capsid proteins to glycosaminoglycans (GAGs) on the cell surface [67].
Specifically, two GAGs, heparan sulphate and chondroitin sulphate B, found on the
surface of all cell types serve as the primary receptors of PCV2 attachment [67, 68].
Following attachment, PCV2 enters monocytic cells via clathrin-mediated endocytosis
[69] and epithelial/endothelial cells via an actin and GTPase-dependent pathway [70].
Once internalized, PCV2 virus-like particles (VLPs) were found to organize into doublemembrane bound intracytoplasmic inclusion bodies likely formed through lysosomal
engulfment of endocytic vesicles [71]. During this first cytoplasmic phase, VLPs were

	
  

	
  

	
  
also found to be associated with both the inner and outer membranes of mitochondria,
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suggesting a potential role of this organelle in facilitating PCV2 replication and
pathogenesis [71]. In fact, mitochondria with diminished functionality containing PCV2
VLPs were observed in the lymph nodes of PMWS-affected animals [72].
PCV2 translocation from the periphery of infected cells to the nucleus is essential
for replication. To do this, PCV2 commandeers a mechanism of intracellular transport
involving the molecular motor dynein, which is used by the host to transport endosomal
cargo along microtubules to the nucleus [73]. Exactly how PCV2 recruits the host
machinery is unclear, however, the viral Cap protein has been shown to play a vital role
in the translocation process. Specifically, the Cap protein induces acetylation of
microtubular α-tubulin [74] and interacts directly with the Intermediate Chain 1 (IC1)
subunit of dynein via residues 42-100 of the Cap protein following disassembly and
release from early endosomes [73]. Inhibition of dynein activity, knockdown of the IC1
subunit, and disruption of the microtubular network were all individually found to
significantly decrease PCV2 replication without affecting internalization and endosomal
uptake of the virions [73].
Upon nuclear entry, VLPs aggregated into non-membrane bound intranuclear
inclusion bodies often in close proximity to networks of protein-like structures [71]. It is
believed that following replication, these protein networks are involved in the
encapsidation of immature virions near the nuclear periphery prior to release back into
the cytoplasm [71]. During this second cytoplasmic phase, double-membrane and triplemembrane bound intracytoplasmic inclusion bodies or viral factories containing VLPs
appear with the assistance of organelle membranes such as the Golgi complex and rough
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endoplasmic reticulum, indicating a potential role of these organelles in the final stages of
viral assembly [71]. Three possible mechanisms of cellular release have been observed
for mature PCV2 virions: 1) VLPs move as a unit within inclusion bodies utilizing
organelle membranes to the plasma membrane for release via budding, 2) PCV2 particles
are released from cytoplasmic inclusion bodies and exit the cell through exocytosis, or 3)
complex cytoplasmic inclusion bodies are formed with various subcellular irregularities
leading to cell lysis and release of PCV2 progeny [71].
The goal and conditional requirements of PCV2 depend on the type of cell
infected. Inhibition of endosome acidification was shown to reduce PCV2 infection in
monocytic cells [69], but enhance PCV2 infection and replication in epithelial cells [75].
This discrepancy in optimal pH may indicate that different proteases are involved in the
disassembly of PCV2 in epithelial and monocytic cells [67]. Furthermore, despite prolific
infection of monocytic cells, PCV2 replication was found to only occur within the nuclei
of epithelial and endothelial cells [76-78]. The reason behind this is believed to be due to
the virus’s reliance on host cell machinery and mitosis for replication since the viral
genome does not encode its own replicative tools and is unable to autonomously
penetrate the nuclear envelope [79]. PCV2 can only achieve nuclear entry at the end of
mitosis when it is incorporated into the nuclei of daughter cells, after which, it must wait
until the cell enters S-phase to hijack host replicative machinery for replication [79]. As a
result, PCV2 likely depends on cells with higher mitotic rates for adequate replication.
Although monocytic cells are not primary sites of viral replication, they are still
main targets of PCV2. Monocytic cells are an essential component of innate immunity,
but also play an important role in initiating adaptive immunity. Specifically, dendritic

	
  

	
  

	
  
cells (DCs) and macrophages engulf antigens at the site of infection, release cytokines
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that enhance the immune response, and then travel to lymph tissues where they present
these processed antigens via surface proteins to activate general and pathogen-specific T
lymphocytes. PCV2 is believed to have immunosuppressive capacity as indicated by the
presence of lymphoid depletion, lesions, and susceptibility to secondary infection.
Immunomodulation of monocytic cells may represent a potential mechanism of PCV2induced immunosuppression by compromising a vital link between the innate and
adaptive immune response to PCV2 and other pathogens.
The ability of PCV2 to accumulate to such high levels in the cytoplasm of
monocytic cells without viral replication indicates inadequate degradation of the virus
following internalization [80]. However, this increase in cytoplasmic PCV2 does not
correspond with increased cell death. Vincent et al. (2003) found that PCV2 was able to
persist within myeloid dendritic cells (DCs), following in vitro inoculation, without
losing infectivity or inducing cell death. They also found no evidence of surface protein
modulation in infected DCs or viral transmission to activated T-lymphocytes [78]. A
similar result was observed in alveolar macrophages (AM); however, the apoptotic rate
was lower in infected AMs compared to controls [81]. It is believed that the silent and
persistent infection of myeloid DCs and capacity to escape degradation in various
monocytic cells may represent a mechanism of PCV2 immune evasion essential for
sustained infection [78, 80]. It has also been proposed that PCV2 utilizes monocytic cells
for systemic dissemination by taking advantage of their normal circulation throughout the
body [64, 78]. Therefore, survival of infected monocytic cells may be imperative for
adequate viral spread and systemic infection.
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Even though PCV2 caused no observable modulation to myeloid DCs, it does

possess immunomodulatory capacity in other types of DCs. Vincent et al. (2005) assessed
PCV2 interactions with a variety of DC subsets, including DC precursors, myeloid DCs,
conventional blood DCs, and plasmacytoid DCs[82]. Once again, no modulation in
myeloid DC antigen presentation or maturation was observed in the presence of PCV2.
However, PCV2 infection of plasmacytoid DCs, also known as natural interferonproducing cells (NIPCs), was found to interrupt a normal costimulatory function required
for myeloid DC maturation in vivo by inhibiting NIPC production of IFN-alpha and TNFalpha following interaction with CpG-oligonucleotides (CpG-ODNs). The exact manner
in which PCV2 disrupts production of these cytokines is unknown, but discovery of
stimulatory and inhibitory CpG motifs within the PCV2 genome may provide some
explanation [83]. One motif in particular was found to inhibit the production of IFNalpha via TLR9 signaling in porcine PBMCs even in the presence of other stimulatory
CpG motifs from the PCV2 genome [83, 84]. However, in a subsequent study the
inhibitory effect of PCV2 was found to not only target CpG-ODN-induced cytokines, but
responses induced by TLR7 and TLR9 agonists as well as other viral pathogens [85].
Also PCV2 DNA and CpG-ODNs did not co-localize within NIPCs during this study,
suggesting they target distinct receptors. Therefore, PCV2 may modulate NIPCs via
unique mechanism to disrupt both autocrine and paracrine maturation of myeloid DCs,
impairing the ability of the host to recognize and respond to simultaneous or secondary
infections [80, 85].
PCV2 has also demonstrated immunomodulatory capacity in alveolar
macrophages (AMs). Chang et al. (2006) found that infected AMs exhibited reduced

	
  

	
  

	
  
phagocytosis and microbicidal capacity leaving the host vulnerable to secondary lung
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infections. The decreased microbicidal capacity is believed to be due in part to impaired
production of reactive oxygen species (ROS) and may illustrate a potential mechanism
utilized by PCV2 to escape degradation within these cells [81]. The infected AMs also
exhibited increased production of cytokines and chemokines involved in enhancing the
inflammatory response and recruiting polymorphonuclear leukocytes (PMNs) and
monocytes to the infection site, such as TNF-alpha, AMCF-II, IL-8, MCP-1, and G-CSF
[81]. Increased expression of these immune signals have also been observed in lymphoid
tissues of PMWS-affected pigs [25, 86, 87], indicating modulation of monocytic cytokine
and chemokine production may contribute to lesion formation by recruiting acute phase
inflammatory cells and other monocytic cells to PCV2-infected tissues [81].
Furthermore, there is a correlation between increased levels of PCV2 in lymphoid
organs of naturally PMWS-affected pigs and lymphocyte depletion and histiocytic lesions
resulting from monocyte infiltration [88]. Darwich et al. (2002) found that the levels of
CD8+ (cytotoxic) and CD4+CD8+ (double positive) T-cells were significantly decreased
in PCV2-positive animals compared to PCV2-negative and healthy controls.
Additionally, the magnitude of lymphocyte depletion and reduction in levels of CD8+ T
cells and IgM+ B cells in peripheral blood were found to correspond with the level of
PCV2 antigen in lymphoid tissues [89]. The mechanisms behind PCV2-induced
lymphocyte depletion remain speculative. As reviewed by Darwich and Mateu (2012)
and X.J. Meng (2013), some studies suggest that apoptosis may be a prominent
mechanism leading to lymphocyte depletion while others provide evidence implicating
reduced proliferation rather than apoptosis as the root source.
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Whether these depletion mechanisms are induced directly by the virus or
cytokines is also highly debated. Studies have shown damage due to PCV2 replication
can directly deplete B and T lymphocytes [90, 91]. However, cytokine imbalances and
alterations have been observed in many lymphoid organs of PMWS affected animals as
well [87]. Specifically, levels of IL-10 have been associated with disease severity and
viral load [92, 93] and over expression of IL-10 mRNA in the thymus was found to
correlate with the degree of lymphocyte depletion and thymic atrophy [87]. PCV2 has
been shown to induce similar alterations in vitro by increasing production of IL-10 and
other pro-inflammatory cytokines and suppressing production of IL-2 and IL-4 by

PBMCs collected from both PMWS-affected and healthy pigs as well as repressing IL-2,
IL-4, and IFN-y production by PBMCs from PMWS-affected pigs compared to healthy
pigs in response to mitogen or superantigen stimulation [86, 94]. Therefore, it is unclear
whether these cytokine imbalances in vivo are caused by PCV2 modulation of infiltrating
monocytes that actually induce depletion or if they are simply a reactive response
resulting from depletion via direct viral-induced mechanisms.

Factors Affecting PCV2 Virulence, Pathogenesis, and Disease Progression
There is significant variation in the virulence of PCV2 isolates, such that simply
being infected with PCV2 does not mean subsequent clinical manifestation of PCVAD.
Assessing virulence is further complicated by the fact that experimental infection with a
PCV2 isolate alone, regardless of its virulence in naturally infected herds, often results in
subclinical infection and rarely in disease [15, 30]. As a result, the virulence of PCV2
isolates is generally quantified based on the level of PCV2 replication and histological

	
  

	
  

	
  
changes rather than symptomatic status [14]. There are four major factors believed to
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influence virulence and related pathogenesis: virus-dependent, host-dependent, secondary
infection, and modulation of innate and adaptive immunity [20]. Since multiple external
factors are presumed to be involved, obtaining consistent findings on isolate virulence
and identifying regions of the PCV2 genome associated with increased virulence has
proven difficult.

a) Virus-Dependent: Variation in Strain Virulence
Grau-Roma et al. (2008) isolated PCV2 from sera of pigs from PMWS affected
farms and non-PMWS affected farms in Spain. They compared the ORF2 sequences of
the 87 isolates and found they could be divided into two different genotypic groups
corresponding to PCV2b (genotype 1) and PCV2a (genotype 2). PCV2b strains were
detected exclusively in PMWS affected farms while PCV2a strains could be found in
both affected and non-affected farms with several pigs from affected farms infected with
both PCV2b and PCV2a strains [15]. Similar reports were made in North America, with
the PCV2 strains isolated from diseased pigs exhibiting high sequence similarity with
PCV2b isolates from Europe and Asia [56, 95]. However, there were also reports that
contradicted these findings. Phylogenetic analysis of 70 PCV2 strains, including 34
strains isolated from pigs with a variety of clinical conditions, found that strains
associated with PMWS were dispersed throughout the phylogenetic tree and often
grouped with strains associated with other diseases and healthy pigs [43]. Experimental
infection of 113 pigs with one of four different PCV2 isolates, two PCV2a and two
PCV2b isolates, showed no difference in virulence between genotypic groups, however,

	
  

	
  

	
  
differences within genotypic groups were observed [96]. Dual inoculation of 20 germ-
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free pigs 7 days apart with PCV2a and PCV2b (2a|2b or 2b|2a), PCV2b (2b|2b), or
PCV2a (2a|2a) showed that heterologous inoculation resulted in increased severity and
incidence of disease compared to inoculation with PCV2a or PCV2b alone [97]. This
indicates that co-infection with PCV2a and PCV2b leads to increased virulence compared
to singular infection and may explain the elevated pathogenicity observed with the
emergence of PCV2b since majority of herds were already infected with PCV2a [8, 14,
97].
Additionally, PCV2a strains have also been associated with clinical symptoms
and exhibit variation in virulence. Opriessnig et al. (2006b) experimentally infected 42
specific-pathogen-free (SPF) pigs with a PCV2a strain isolated from a pig with no PCV2associated lesions (PCV2-4838) and a PCV2a strain isolated from a pig with PCV2associated lesions and disease symptoms (PCV2-40895). Sequence comparison revealed
a total of 20 nucleotide differences between the two strains: 5 in ORF1, 14 in ORF2, and
one in ORF3 resulting in 99.4%, 96.1%, and 99.7% amino acid sequence homologies,
respectively. They found significant evidence based on severity of microscopic lesions
and level of PCV2 and antibodies in serum that the PCV2-40895 isolate was more
virulent than the PCV2-4838 isolate, indicating that PCV2a can be pathogenic and
variation in virulence between even genetically similar isolates exists [9].
The occurrence of novel strains with increased virulence pose a constant threat
due to the high mutation rate of PCV2 [49]. Majority of genetic differences between
strains present today are located within ORF2, occasionally altering the amino acid
sequence of the capsid protein. Additionally, the ORF2 sequences of PCV2a strains were

	
  

	
  

	
  
found to be more variable than PCV2b strains, indicating PCV2b may represent the

23

evolution of PCV2a towards increased virulence [15, 96, 98]. In fact, comparison
between archival PCV2 strains from 1970-1971 and contemporary PCV2 strains
uncovered a consistent 9bp sequence difference in an immunogenic epitope of ORF2,
altering configuration of the nucleocapsid from hydrophilic in archival strains to
hydrophobic in contemporary strains [99]. Experimental infection of gnotobiotic pigs
with PCV2 clones illustrated that the archival PCV2 strains were avirulent compared to
contemporary PCV2 strains [99]. Additional support for the role of Cap sequence
variation in isolate pathogenicity is given by several studies that illustrate as few as one
or two amino acid substitutions in the Cap protein is sufficient to cause alterations in
PCV2 virulence [100-102]. Thus, comparison of ORF2 sequences between current PCV2
isolates has been a major area of focus in attempt to identify specific regions associated
with virulence.
Larochelle et al. (2002) identified three different regions of the Cap protein with
increased amino acid heterogeneity, positions 59-80, 121-136, and 180-191 [43]. Two of
these regions overlap with dominant immunoreactive areas at positions 65-87 and 113147 previously identified using Pepscan [103]. In fact, majority of differences between
isolates from healthy and diseased pigs are located within immunogenic epitopes of the
Cap protein [30, 45]. However, after further analysis no consistent amino acid motifs
within these regions were found that could be associated with PCV2 isolates from pigs
with PMWS or other disease symptoms [43]. In another study, Grau-Roma et al. (2008)
identified three similar regions of high heterogeneity between ORF2 sequences at amino
acid positions 57-91, 121-136, and 185-191. Alignment revealed amino acid sequence

	
  

	
  

	
  
patterns in these regions that were specific to either PCV2a or PCV2b. As previously
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stated, the PCV2a sequences were more variable within these regions while the PCV2b
sequences were more conserved between isolates. Once again they were unable to detect
any association between the PCV2b sequence found in individual pigs and disease status
[15]. Similar outcomes were also reported following phylogenetic analyses of Dutch [53]
and French isolates [98]. This recurrent inability to identify genetic signatures of PCV2
virulence suggests that external factors have significant influence over virulence and the
outcome of infection.

b) Innate and Adaptive Immunity in PCV2 Infection
PCV2 infection has been shown to induce a humoral immune response, a facet of
adaptive immunity illustrated by antibody production, which in subclinically infected
pigs results in decreased viral titers [65, 88, 104]. Generally, specific IgM antibodies are
the first to appear in serum and represent recent or on-going infection, while specific IgG
antibodies are detected later on and represent the animals immune status for a particular
pathogen, such as prior exposure or vaccination. Progranichnyy et al. (2000) intranasally
and intramuscularly inoculated five 8-week old colostrum deprived pigs free of any major
swine pathogens with a strain of PCV2 isolated from a pig diagnosed with PMWS. PCV2
viremia could be detected at 7, 14, and 21 dpi, but not at 28 dpi. PCV2-specific
antibodies were first detected at 14 dpi, however, the presence of PCV2-neutralizing
antibodies was not observed until 28 dpi [104]. A similar result was obtained by McKnite
et al. (2014), with PCV2-specific IgM antibodies present at 14 dpi, peaking at 21 dpi and
dropping again at 28 dpi and PCV2-specific IgG or neutralizing antibodies present at 21
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dpi followed by an increase in levels at 28 dpi. Although viremia was still detected at 28
dpi in this study, it had significantly decreased in level compared to 14 and 21 dpi [65].
In fact, a positive phenotypic correlation was found between overall viral load and IgM
(r=0.26 to 0.34, 14-28 dpi, P<0.0001) and IgG (r=0.17 to 0.20, 21-28 dpi, P<0.01) during
the challenge [65]. However, variation in the level and type of adaptive immunity
between animals has been observed and may play a significant role in the efficacy of
PCV2 replication and virulence.
Meerts et al. (2005) infected 12 gnotobiotic pigs with PCV2 and treated 4 of these
pigs with cyclosporine A (CysA) in order to assess the influence of adaptive immunity on
PCV2 replication. All CysA treated pigs had higher viral titers compared to the nonCysA treated pigs, suggesting adaptive immunity plays a central role in limiting viral
replication [88]. They also observed several different replication and antibody profiles
among the non-CysA treated pigs. No PCV2 could be detected in the two pigs with the
highest neutralizing antibody titers present at 15 dpi along with a significant increase in
IFN-y mRNA at 15 dpi. Five pigs with lower neutralizing antibody titers and no
detectable increase in IFN-y, had low to moderate PCV2 titers at 15 dpi that either
plateaued or decreased as time progressed. A single pig exhibited no neutralizing
antibodies or rise in IFN-y and had a low PCV2 titer at 15 dpi that drastically increased at
21 dpi. Since a higher level of viral replication is associated with increased potential of
disease progression, this study suggests that the outcome of infection may be partially
contingent upon the adaptive immune response of the host [88].
Meerts et al. (2006) went on to further investigate the correlation between viral
replication and lack of neutralizing antibodies in a subsequent study comparing

	
  

	
  

	
  
experimentally infected SPF pigs, naturally PMWS-affected pigs, and healthy controls.
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No PCV2-neutralizing antibodies were found in the naturally infected PMWS-affected
pigs and only low neutralizing antibody titers could be observed between 7 and 14 dpi in
the experimentally infected PMWS-affected pigs. This differed from the healthy and
subclinically infected pigs, which exhibited neutralizing antibody titers corresponding
with that of total antibodies [105]. They also found that the IgM profiles differed between
healthy and affected pigs, with IgM increasing throughout the study in
healthy/subclinically infected pigs and decreasing or remaining at low levels in affected
pigs [105]. A similar result was found by Fort et al. (2007), such that PMWS-affected
pigs had negative or significantly lower neutralizing antibody titers than healthy animals
and a suggestive inverse correlation between neutralizing antibody titers and viral load.
In addition, PCV2-specific IgG titers were positively correlated with neutralizing
antibody titers (r=0.76, P<0.0001), while no correlation was observed between IgM and
neutralizing antibody titers [106]. Together, these studies illustrate that there is a
difference in the humoral response between subclinically infected pigs and clinically
affected pigs with the level of viral replication and incidence of disease increasing in the
absence of PCV2-neutralizing antibodies [88, 105, 106]. Whether these differences in
adaptive immunity are simply due to variation in host immune responses or variation in
efficacy of PCV2 immunomodulation between hosts is still unclear.
Natural mechanisms of active and passive immunity have also been shown to
decrease host susceptibility to PCV2, including prior PCV2 infection [96] and PCV2specific maternal antibodies [107, 108]. In the second part of the study conducted by
Opriessnig et al. (2008), they initially inoculated pigs with either a PCV2a or PCV2b

	
  

	
  

	
  
isolate then re-inoculated the animals 5 weeks later with the other isolate and compared
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the responses to pigs without prior exposure. Viral replication of the secondary isolate
was almost completely blocked in the re-inoculated pigs, indicating prior infection not
only provided protection against subsequent infection by way of active immunity, but
that cross-protection between PCV2a and PCV2b isolates also exists [96]. Several studies
have also noted a potential litter effect for PMWS susceptibility and mortality [107, 109].
It is known that newborn piglets are protected by passively acquired maternal antibodies
from a variety of viral pathogens [108]. Therefore, sow infection or vaccination status
and as a result maternal antibody titer have also been associated with piglet disease
susceptibility.
McKeown et al. (2005) experimentally infected 24 piglets split into 4 groups
based on maternal antibody titer at 12 days of age: group A were negative, group B had
low levels, and groups C and D had high levels of maternal antibodies. Groups A, B, and
C were inoculated at day 0 with PCV2 and then re-infected at day 42. Group D was only
infected at day 42. Viremia prior to day 42 was detected in nearly all group A and B
piglets, but in only 2 of 8 group C piglets. Following re-infection or initial inoculation
(group D) at day 42, viremia was observed between 7 and 21 dpi in nearly all group A, B,
and D piglets, but only 3 of 8 group C piglets [108]. All groups except for group C tested
negative for PCV2 maternal antibodies at day 42 [108]. Sow antibody titer was also
associated with piglet mortality in naturally PMWS-affected farms, such that the piglets
from sows with medium to high antibody titers had significantly lower death percentages
than those from sows with low antibody titers [107]. These results indicate that higher
titers of PCV2 maternal antibodies provides greater protection against early PCV2
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infection and that a combination of high PCV2 maternal antibody titer and prior exposure
to PCV2 decrease susceptibility to secondary PCV2 infection by extending the length of
protection supplied by the maternal antibodies [108].

c) Immunostimulation and Secondary Infections in PCVAD
Coinfection with secondary pathogens or extraneous immunostimulation with
adjuvants or vaccines have been shown to fuel the development and severity of PCVAD
[30]. These factors are often required for PCV2 infected animals to display clinical
symptoms, which has led many to question if PCV2 is actually the etiological agent
behind these diseases. The widespread infection of PCV2 in even asymptomatic herds
and variation in PCVAD symptoms further complicated its discovery and association
with disease [110]. Studies have revealed that although PCV2 alone often results in
subclinical infection, it is the common and crucial component of PCVAD development
[20, 111].
In 2004, Opriessnig et al. (2004b) assessed the effect of dual infection with
Mycoplasma hyopneumoniae and PCV2 on development of PMWS. They randomly
assigned 67 pigs to 4 groups consisting of a control group (n=17), a M. hyopneumoniae
group (n=17), a PCV2 group (n=16), and a dual M. hyopneumoniae/PCV2 group (n=17).
The pigs were inoculated with M. hyopneumoniae at 4 weeks of age and/or PCV2 at 6
weeks of age. The dual-infected pigs presented with reduced weight gain, labored
breathing, and lethargy. Compared to the other groups, the dual-infected pigs had
significantly more severe macroscopic lung lesions, microscopic PCV2-associated lung
and lymphoid lesions, and increased amounts of PCV2-antigens associated with the

	
  

	
  

	
  
lesions. Four of the 17 dual-infected pigs also had symptoms characteristic with PMWS
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such as severe lymphoid depletion, reduced growth rate, and granulomatous
lymphadenitis associated with high levels of PCV2-antigen. These findings, indicate that
M. hyopneumoniae exacerbates PCV2-associated lung and lymphoid lesion severity and
promotes increased and sustained levels of PCV2 antigen leading to increased incidence
of PMWS [17].
In 2002, pigs with systemic PCVAD were assessed for pathogens and it was
found that M. hyopneumoniae was detected in 36% of the 484 cases, whereas singular
PCV2 infection was detected in only 2% of cases [112]. Other common pathogens that
were associated with PCV2 coinfection in this study included Porcine Reproductive and
Respiratory Syndrome Virus (PRRSV) found in 52% of cases, bacterial septicemia or
pneumonia in 22% of cases, and Swine Influenza Virus (SIV) in 5.4% of cases [112].
Based on these findings, it is common opinion that there is no secondary pathogen that is
solely responsible for inducing incidence and severity of PCV2-associated diseases [20].
Rather, it is believed several pathogens that vary from location to location are capable of
eliciting PCVAD development [20].
Experimental infection of gnotobiotic pigs with PCV2 alone generates only
subclinical to mild symptoms with little dissemination of viral antigen, however, when
gnotobiotic pigs are co-infected with PCV2 and porcine parvovirus (PPV) they present
with moderate to severe symptoms and widespread dissemination of PCV2 antigen in
lymphoid tissues and histiocytic lesions [113]. Since experimental infection of
conventional pigs with PCV2 has been occasionally successful at inducing PMWS
symptoms, but a secondary pathogen is required to elicit disease symptoms in gnotobiotic
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pigs, Krakowka et al. (2001) proposed that increased PCV2 replication and dissemination
in vivo requires immune stimulation mediated by monocytic cell activation in lymphoid
tissues. To test this hypothesis, they performed a short-term experiment to assess the
effect of local immunostimulation on viral replication and dissemination and a long-term
experiment to assess the effect of systemic immunostimulation on incidence of PMWS
[110].
For the short-term experiment, Krakowka et al. (2001) inoculated 7 piglets with
PCV2 at 1 day of age. At 3 and 7 days of age, piglets were injected in the left hip and
shoulder with either the immunostimulant keyhole limpet hemocyanin (KLH), an
irrelevant antigen, emulsified in incomplete Freund’s adjuvant (ICFA) or KLH in saline.
Viral load was then assessed at 13-14 dpi in local lymph nodes draining injection sites
and contralateral lymph nodes, so that each pig served as its own control. The amount of
recovered infectious virus was highest in draining lymph nodes of KLH/ICFA injection
sites compared to contralateral lymph nodes and compared to pigs injected with KLH in
saline. Furthermore, PCV2 was found in distal lymph nodes of animals injected with
KLH/ICFA, but only sparsely distributed in distal lymph nodes of animals injected with
KHL in saline. For the long-term experiment, they inoculated 10 piglets at 1 day of age
with PCV2. At 3 and 7 days of age, piglets were injected in both hips and shoulders to
achieve systemic immunostimulation with either KHL/ICFA alone or KHL/ICFA
followed by intraperitoneal (IP) injections of thioglycollate broth (glycan) at 10 and 20
days of age to stimulate peritoneal macrophages. All immunized pigs (both KLH/ICFA
and KLH/ICFA-IP glycan) infected with PCV2 developed PMWS by 35 days of age
while none of the infected pigs that were not immunized developed PMWS. Through

	
  

	
  

	
  
these experiments, Krakowka et al. (2001) illustrated that immunostimulation enhanced
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PCV2 replication in local lymph nodes as well dissemination to distal lymphoid tissues
and that systemic immunostimulation, with or without macrophage activation, triggered
the development of PMWS in PCV2-infected gnotobiotic pigs, indicating that immune
activation is essential for PCV2 pathogenesis [110].
Immunostimulation by way of vaccination or adjuvant administration increases
lymphocyte proliferation [114]. This mechanism could explain the correlation between
increased viral antigen and immunostimulation since PCV2 replication may increase in
dividing cells. However, another study assessing the effects of immunostimulation on
PMWS development in SPF piglets did not find any difference in incidence or severity of
disease between piglets that had been subjected to the immunizing agent, KLH/ICFA,
and those that had not, suggesting immunostimulation is not an important factor in
PMWS development [115]. In 2005, a reverse transcription PCR (RT-PCR) assay able to
detect the presence of PCV2 capsid mRNA was developed and allowed the researchers to
be able to discern between replicating PCV2 and PCV2 virions within PK-15 cells [116].
This knowledge was used in subsequent studies to quantify the amount of Cap mRNA
within PBMCs using a quantitative real time PCR (qPCR) assay in order to better assess
the impact of immunostimulation [114, 117].
In vitro inoculation with PCV2 showed that viral replication was significantly
increased in PBMCs that had been stimulated with concanavalin A (ConA) compared to
resting PBMCs [117]. However, the magnitude of increase in viral replication within
stimulated PBMCs was later found to depend on the mitogen used and independent of
cell proliferation since similar levels of Cap mRNA were found in proliferating and non-

	
  

	
  

	
  
proliferating cells [114]. Interestingly, they also found that PCV2 infected PBMCs
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stimulated with pokeweed mitogen (PWM) exhibited increased apoptosis compared to
uninfected or unstimulated infected PBMCs. In fact, PBMCs infected with PCV2 alone
without stimulation exhibited reduced levels of apoptosis compared to non-infected
PBMCs [114]. These findings indicate that immunostimulation increases PCV2
replication, supporting the in vivo study conducted by Krakowka et al. (2001). However,
the mechanism that induces this replication appears to be independent of lymphocyte
proliferation [114]. In addition, certain stimulation increased apoptosis compared to
infection alone [114]. Although this has not yet been tested in vivo, it may indicate that
immunostimulation plays an even greater role in PCV2 pathogenesis than originally
thought.
The question of whether PCV2 immunosuppression enables secondary infections
that exacerbate disease symptoms or secondary infections stimulate PCV2 replication and
pathogenesis is analogous to the age old question of what came first: the chicken or the
egg? The answer seems to change depending on the angle from which you view it. The
illustrated importance of immunostimulation and wide variety of secondary pathogens
capable of eliciting PCVAD symptoms suggest that secondary infections may simply
provide the required stimulation of the immune system to enhance PCV2 pathogenesis. In
this case, pathogenesis would not be contingent upon a specific secondary pathogen, but
on the type of stimulation provided by that secondary infection. Immunosuppression was
also shown to promote PCV2 replication and spread, however, when a stronger
immunosuppressant was used, characteristic PCVAD inflammatory reactions were not
observed [118, 119]. Therefore, the degree of immunosuppression, immunostimulation,

	
  

	
  

	
  
and time of secondary infection may all contribute to the pathogenic outcome of PCV2
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infection.

d) Host-Dependent: Role of Host Genetics in PCV2 Susceptibility
Although PCV2 infection is widespread amongst all pigs, the progression from
subclinical infection to PCVAD has been shown to vary between breeds and individuals.
This indicates that genetic variation between breeds, populations, and individuals may
play a significant role in host susceptibility to PCV2 infection and subsequent incidence
and severity of disease.
Opriessnig et al. (2006a) compared the susceptibility of three different breeds of
pigs to PCV2 infection. In this study, they selected 75 colostrum fed, purebred female
pigs raised under identical conditions from a single farm consisting of Duroc (n=26),
Landrace (n=25), and Large White (n=24). Twelve of these pigs (3 Duroc, 6 Landrace,
and 3 Large White) were mock inoculated and the remaining 63 pigs (23 Duroc, 19
Landrace, and 21 Large White) were experimentally infected intramuscularly and
intranasally with PCV2 at 5-7 weeks of age. The control pigs were kept together in a
room separate from the infected pigs. Clinical evaluation was conducted daily while
weights and serum samples were collected 7, 14, 21, 28, and 35 dpi. Half of the infected
and control pigs from each breed were necropsied at 21 dpi and the other half at 35 dpi.
Similar macroscopic and microscopic lesions including enlarged lymph nodes,
granulomatous inflammation, and lymphoid depletion were observed in all 3 breeds.
However, lymphoid depletion was significantly more severe in Landrace compared to
Duroc and Large White. Additionally, 3 of the 19 Landrace pigs developed severe

	
  

	
  

	
  
lymphoid lesions containing high levels of PCV2 antigen, which are characteristic of
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PMWS. None of the Duroc or Large White individuals exhibited such lesions. Therefore,
the 3 breeds were determined to be equally susceptible to subclinical PCV2 infection, but
Landrace were more susceptible to developing clinical PMWS [120].
In a subsequent study, Opriessnig et al. (2009) went on to compare susceptibility
of Landrace and Pietrain pigs to PCV2. Together they had 39 Landrace and 39 Pietrain
pigs that were divided into 4 groups: Landrace non-inoculated negative control (n=13),
Pietrain non-inoculated negative control (n=13), Landrace-PCV2 (n=26), and PietrainPCV2 (n=26). The Landrace-PCV2 and Pietrain-PCV2 groups were inoculated with
PCV2 at 21 weeks of age and blood samples were collected weekly for 3 weeks post
infection. Serum samples were tested for PCV2-specific IgG and IgM antibodies,
neutralizing antibodies, and PCV2 viremia. Plasma samples were tested for certain
cytokines. All groups of pigs were necropsied at 21 dpi. Clinical disease was not
observed in any of the animals and the presence of macroscopic lesions did not differ
between breeds. No differences in PCV2-specific IgG and IgM levels, neutralizing
antibodies, viremia, or cytokine concentrations were observed between breeds. Both
PCV2 groups had significantly more severe lesion scores than the control groups, but the
Pietrain-PCV2 group had significantly less severe microscopic lesions than the LandracePCV2 group. Only about 34.6% of the Pietrain-PCV2 group had mild follicular depletion
in lymph nodes along with a low level of PCV2 antigen while the remaining 65.4%
exhibited normal lymphoid tissues. On the other hand, 30.7% of the Landrace-PCV2
group exhibited moderate to severe lymphoid depletion and histiocytic replacement along
with moderate lymphohistiocytic infiltration of the heart and liver tissues. These results

	
  

	
  

	
  
indicate that there is a difference in susceptibility to PCV2-associated lesions between
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Landrace and Pietrain pigs [121], supporting their previous findings suggesting a genetic
component to PCVAD susceptibility [120].
In 2005, Rose et al. conducted a study in France to assess the presumed protective
effect of the Pietrain breed against PMWS. They selected 4 PMWS-affected farms in
France and randomly inseminated sows with either pure Pietrain semen or non-Pietrain
semen normally used on the farm (semen X). One of the farms had a third genetic type of
semen (Y) that was used in addition to the Pietrain and X semen. This experiment was
carried out in 2 batches per farm for a total of 8 batches. A total of 30 pigs per paternal
genetic group stratified by litter (n=2) were selected from each batch. This resource
population of 540 piglets were then housed in identical conditions, observed for clinical
symptoms, and weighed from birth to slaughter. Blood samples were taken at age of
weaning, 7, 13, 16, and 21 weeks of age and then again at slaughter and tested for PCV2specific antibodies. A portion of the resource population that exhibited the best growth
performance and assumed to be unaffected by significant disease were selected as a
reference group used to account for inherent differences in growth performance between
genetic groups. The average incidence rate of PMWS was 18% with no significant
differences in age of onset or morbidity between the paternal genetic groups [21].
However, the time it took for PMWS to develop was found to be influenced by PCV2
seroconversion and associated with maternally acquired passive immunity [21],
corroborating the impact of maternal effects on PMWS incidence and survival [107, 108].
Therefore, the inability to detect a significant paternal genetic effect in this study may
have been due in part to confounding maternal effects. Taking this into account, the

	
  

	
  

	
  
observed difference in morbidity between Pietrain-derived and X-derived offspring,
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16.3% and 17.3% respectively, may indicate a genetic source of reduced PMWS
susceptibility in the Pietrain breed [21].
To further investigate the effect of host genetics on PCVAD progression,
McKnite et al. (2014) performed the first genome wide association study (GWAS) to
identify genomic regions associated with PCV2 susceptibility. The resource population
was comprised of 4 batches of crossbred pigs derived from various commercial lines
(Nebraska Index Line (NIL), Landrace, Large White, and Duroc). A total of 386 pigs
across the batches were experimentally infected intranasally and intramuscularly at 5
weeks of age with PCV2b and were weighed and monitored for clinical symptoms. Blood
samples were taken weekly over the course of the 28-day challenge to assess for PCV2
specific IgM and IgG antibodies and PCV2 viremia. All pigs were genotyped for
approximately 61,177 SNPs using the Illumina Porcine SNP60 BeadArray. After filtering
to remove low quality SNPs and DNA samples, a total of 370 samples and 56,433 SNPs
were used for GWAS. Using a Bayes B model, SNP effects were measured in 1Mb
windows and then combined to get the proportion of genetic variance for each indicator
trait of PCVAD susceptibility: weekly viremia, PCV2-specific IgG and IgM antibody
levels, and Average Daily Gain (ADG) as well as overall viral load and ADG. Host
genetics was found to explain significant proportions of phenotypic variation for both
viremia (35-59%) and PCV2-specific antibody levels (10-59%), however, the proportion
varied across weekly measurements. In addition, multiple loci (1Mb windows) were
found to contribute to the phenotypic variation for each of the target traits, with some
unique to specific traits and common between traits. Specifically, windows on SSC1,
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SSC7, and SSC12 affected viral load and/or specific weekly viremia measurements while
windows on SSC12, SSC14, and SSCX affected weekly IgM and IgG [65].
McKnite et al. (2014) hypothesized that loci influencing viral replication and
accumulation would indirectly affect the immune response and weight gain of individuals
over the course of the PCV2 challenge. They assessed genomic correlations between
PCVAD indicator traits and found that viral load had a significant negative genomic
correlation with ADG (r=-0.21 to -0.24, 0-14 dpi, P<0.0001) and positive genomic
correlation with IgM (r=0.22 to 0.54, 14-28 dpi, P<0.0001) and IgG (r=0.29 to 0.43, 2128 dpi, P<0.0001). Single marker association was performed using 31 SNPs with
significant effects on viral load to estimate pleiotropic effects across the indicator traits
[65]. Of these SNPs, 41.9% had effects on two or more measurements of weekly viremia,
35.5% had effects on overall ADG or at least one measurement of weekly ADG, 16.1%
had effects on one or more measurements of IgM, and 19.4% had effects on one or more
measurements of IgG [65]. In addition, the combined effect of 3 SNPs located on SSC9
and SSC12 that captured the negative relationship between viral load and ADG indicated
that individuals with more favorable alleles at these loci would have lower weekly
viremia and viral load and higher weekly and overall ADG [65].
This study was expanded with the incorporation of additional maternal lines from
North-American swine breeding programs, which doubled the amount of samples
(n=974) used in the GWAS [122]. Following the same protocols as described in McKnite
et al. (2014), this study found that the SNP genotypes explained a larger proportion of
phenotypic variation for overall viral load (64%) than detected by the previous study
[122]. Additionally, they uncovered two major SNPs on SSC12 and SSC7 that explained
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11.5% and 2.8% respectively of the genetic variation for viral load [122]. Although, the
proportion of phenotypic variation in ADG explained by the SNP genotypes was still
limited, there was once again a negative correlation between viral load and overall ADG
(r=-0.36, P <0.0001), partially explained by the major SNPs. Specifically, animals with
the CC genotype for the major SSC12 SNP, exhibited lower viral load (P<0.0001) and
higher overall ADG (P<0.05) compared to the heterozygous (CT) or alternate
homozygous (TT) genotypes [122].
Building on the findings of McKnite et al. (2014) and Engle et al. (2014), a
subsequent study went on to assess the role of host genetics in the level of the proinflammatory cytokine, TNF-alpha, known to be modulated in PCV2 infected animals
[123]. Initially, the protein serum TNF-alpha levels were measured weekly in 6 pigs with
high viral load and low ADG and 6 pigs with low viral load and high ADG. A significant
difference in TNF-alpha level at 21 dpi was observed between the two groups. TNF-alpha
levels were profiled from another 297 pigs within the resource population and found to be
phenotypically positively correlated with viral load (r=0.25, P<0.001), viremia (r=0.15 to
0.28, 14-28 dpi, P<0.05), IgM (r=0.20 to 0.34, 14-28 dpi, P<0.001), and IgG (r=0.11 to
0.19, 21-28 dpi, P<0.05) antibody levels and negatively correlated with overall ADG (r=0.16, P<0.05). The GWAS for TNF-alpha at 21 dpi revealed a substantial proportion of
the phenotypic variation (73.9%) could be explained by the 56,433 SNPs. Major effect
windows were located on SSC8, SSC10, and SSC14, however, no single window
accounted for majority of the effect [123]. The lack of association surrounding the TNFalpha locus on SSC7 suggests that the host genetic factors controlling this variation in

	
  

	
  

	
  
TNF-alpha at 21 dpi in response to PCV2 infection act through mechanisms of trans-
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modulation.
The ability to identify QTL associated with various indicator traits of PCV2
susceptibility support the notion that host genetics plays a critical role in disease
progression. Specifically, QTL on chromosomes 7 and 12 were identified for weekly
viremia, antibody levels, and overall viral load following experimental PCV2 infection
[122]. Further investigation of QTL such as these may lead to the identification of genes
and polymorphisms responsible for reduced PCV2 susceptibility and better our
understanding of PCV2 pathogenesis. Together this knowledge has the potential to enable
the development of more efficient molecular solutions to better combat and prevent
PCV2 in the future.

Current PCV2 Management and Vaccines
PCV2 was found to be resilient to multiple common disinfectants, such as ethanol
[124]. This resilience combined with persistent subclinical infection makes control and
prevention of PCV2 outbreaks difficult. Even with effective disinfectants, such as bleach,
it is impossible to completely disinfect facilities of PCV2 and prevent shedding by
subclinically infected animals through fecal, urinary, and oronasal routes [58, 59, 124].
Therefore, although facility management is an important factor in preventing PCV2
outbreaks, there is only so much that can be done to prevent this elusive pathogen. As a
result, majority of management practices at the present time revolve around vaccination
regimes for the entire herd for both PCV2 and secondary pathogens.
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There are a variety of commercial PCV2 vaccines currently on the market
including: Ingelvac® CircoFLEX™, Porcilis® PCV, Suvaxyn PCV2® One Dose,
Circumvent PCV™, and Circovac®. Both Ingelvac® CircoFLEX™ (Boehringer
Ingelheim) and Circumvent PCV™ (Intervet) are subunit vaccines utilizing killed
baculovirus vectors injected into the host to prevent against PCV2 replication and

shedding. The antigen of these vaccines is generated by incorporation of the ORF2 gene
that encodes the PCV2 capsid protein into the baculovirus vector. Ingelvac®
CircoFLEX™ is a single dose (1 mL) vaccine administered intramuscularly to piglets 3
weeks of age or older (Boehringer Ingelheim). Circumvent PCV™ can be administered
intramuscularly either as a single dose (2 mL) at 3 weeks of age or as a double dose
vaccine (2 mL) as early as 3 days of age followed by a second injection (1 mL) 3 weeks
later (Intervet). Circumvent PCV™ was tested in a randomized controlled clinical trial in
a herd of pigs with history of PCVAD [125]. They found that vaccinated pigs had
significantly lower mortality rates (50% reduction) and higher ADG (9.3% increase)
during the finishing phase compared to control pigs. Vaccinated pigs were also found to
weigh on average 8.8kg more at time of marketing [125]. Porcilis® PCV (Intervet
International) is another subunit vaccine that contains the capsid protein of a PCV2b
strain. This vaccine was found to prevent viremia against 4 different PCV2 genotypes
originating from different geographic locations as well as reduce both nasal and fecal
PCV2 shedding [126]. However, Porcilis® PCV is a double dose vaccine with the first
injection (2 mL) administered at 3 weeks of age and the second injection (2 mL)
administered 2-3 weeks later (Intervet), which may increase stress for the individual
animal. Suvaxyn PCV2® One Dose is a killed-recombinant vector vaccine that contains a
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porcine circovirus type 1-2 chimera as the antigen and is administered intramuscularly in
a single dose (2 mL) at 3 weeks of age or older (Fort Dodge® Animal Health).
Circovac® is a ‘whole-virus’ vaccine that contains inactivated porcine circovirus type 2
and a mineral oil adjuvant administered in two doses 3 to 4 weeks apart to gilts and sows
prior to breeding (Merial).
Various studies have been conducted to compare the effectiveness of different
commercially available vaccines. In 2009, Takahagi et al. compared the effects of
Ingelvac® CircoFLEX™ and Porcilis® PCV on different PCV2 genotypes in Japanese
commercial pig farms. Mean mortality rates 8 months after implementation of
vaccination programs decreased in farms infected with PCV2a-2 (from 20.8% to 12.1%)
and PCV2b (from 26.5% to 13.7%), but did not significantly change in farms infected
with PCV2a-1 (from 14.7% to 14.1%). This indicates that vaccines can effectively
reduce mortality rates associated with PCV2; however, the effectiveness may be
dependent upon the PCV2 genotype in question [127].
In 2011, a study was conducted by Lyoo et al. that compared the effectiveness of
Suvaxyn PCV2® One Dose, Circumvent PCV™, and Ingelvac® CircoFLEX™. A total
of 80 pigs were divided into four groups, with three groups receiving one of the vaccines
at 3-weeks of age following the manufacturers protocol and the other acting as a control
group. All three vaccinated groups had significantly lower PCV2 viremia compared to
the control group at 22 weeks of age [128]. In addition, groups that received Circumvent
PCV™ or Ingelvac® CircoFLEX™ exhibited increased ADG (0.81kg or 0.80kg,
respectively) compared to the control group (0.74kg, P<0.05). Another study compared
the same three vaccines, however, also assessed the effects of single and double dose for
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the Suvaxyn PCV2® vaccine [129]. A total of 60 3.5-week old piglets were divided into
groups and received a different vaccine or vaccine dosage. Overall, they found that
viremia was reduced by 78.5% in pigs receiving single dose vaccines (Ingelvac®
CircoFLEX™ and Suvaxyn PCV2® One Dose) and 97.1% in pigs that received double
dose vaccines (Circumvent PCV™ and Suvaxyn PCV2®). They also observed a
reduction in microscopic lymphoid lesions by 78.7% for single dose and 81.8% for
double dose vaccines [129]. Together, these results indicate that both single and double
dose vaccines significantly reduce PCV2 viremia and improve the growth and overall
wellness of the animals.
However, vaccines are not a cure all in terms of PCV2. As illustrated above, there
are no commercially available vaccines capable of complete eradication of PCV2 viremia
[130]. This poses a potential control problem since PCV2 can be transmitted or cause
complications at even low levels. Specifically, one study identified a new PCV2 disease
syndrome associated with herds vaccinated for PCV2, called Acute Pulmonary Edema
(APE) [131]. This syndrome was first discovered in 8 farms across Kansas and Nebraska
in piglets as young as 7-weeks of age. High levels of PCV2 DNA, but no other pathogens
were detected in the sera and tissues of all APE affected pigs. Unlike other PCVAD, APE
has preacute onset and results from transmission of PCV2 to young piglets prior to
vaccination age that do not have adequate maternally derived-antibodies for protection
[131].
In regards to female reproductive failure, re-vaccinating gilts 3-weeks prior to
integration into the breeding herd did not influence the proportion of mummified or still
born fetuses in affected herds with increased rates of reproductive failure attributed to

	
  

	
  

	
  
PCV2 [130]. Rather, findings based on an unaffected herd from this same gilt source
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suggested that flow strategies maybe a better solution. These gilts were integrated into the
breeding herd 9 weeks younger than gilts from the affected herds and showed no increase
in fetal mortality or mummification, indicating that when gilts are introduced into the
breeding herd prior to breeding may impact PCV2-associated reproductive failure [130].
The reason being that younger gilts have time to recover from PCV2 exposure prior to
breeding, which protects the fetuses from vertical PCV2 transmission [130]. Although
current vaccines are fairly effective, they are not full proof, which is why further research
to better understand PCV2 pathogenesis is crucial for future prevention of this small, but
mighty pathogen.
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CHAPTER 2
ANNOTATION OF QTL REGION LOCATED ON CHROMOSOME 12
AND POLYMORPHISM DISCOVERY UNCOVERS CANDIDATE
GENES AND NOVEL POLYMORPHISMS INFLUENCING IN VIVO
PCV2 REPLICATION*

*Parts of this chapter were submitted to PLOS Genetics (2018)
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2.1 Introduction
Anecdotal field data and initial experimental evidence [1, 2] described differences
between breeds in both incidence and severity of PCVAD [3], supporting the role for host
genetic variation in the etiology of the disease. In the first genome-wide association study
(GWAS), host genetics was found to influence PCV2 titer and accounted for an important
proportion of the phenotypic variation (~45%) for viral load [4]. In addition, substantial
variation in the timing and magnitude of immune response was also observed [4, 5]. A
subsequent study [5] extended this work by examining the influence of host genetics on
the process of infection, based on a combination of the two previous study populations
(n=974 F1 crossbred pigs originating from 14 genetic lines) challenged by experimental
infection with the same PCV2b strain and genotyped with a high-density array (Porcine
SNP60 BeadArray, 56,433 SNPs). The population structure provides substantial variation
in linkage disequilibrium (LD) decay in order to potentially identify genomic regions that
influence PCV2 susceptibility using a GWAS approach. In this study, we build on the
findings of Engle et al. (2014) using both genomic and RNA sequencing, gene
annotation, and polymorphism discovery to dissect the genomic regions associated with
PCV2 viral load on chromosome 12 to further elucidate the role of host genetics in
disease progression.
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2.2 Materials and Methods
Experimental Design: Animals, Diets, and Housing
Experimental PCV2b challenge was conducted in nine batches that varied in size
from 81 to 141 pigs. The genetic makeup of this resource population consisted of 974 F1
crossbred pigs produced by 14 genetic lines generated by seven genetic programs.
Batches 1-4 (n=386) were produced by the UNL Swine Research Unit involving Large
White, Landrace, and Duroc commercial pigs as well as pigs from the Nebraska Index
Line (NIL), a line selected primarily for litter size [4]. Batches 5-9 (n=588) were
produced with genetics from PigGen Canada Consortium, which used Large White dams
and Landrace sires [5].
The dams of the experimental pigs had been vaccinated for PCVAD at 3 weeks of
age with a single dose of Ingelvac CircoFLEX vaccine (Boehringer Ingelheim). The
suppliers of the pigs also had vaccination programs for Porcine parvovirus, Erysipelothrix
rhusiopathiae, Clostridium perfringens, Leptospirosis and Colibacillosis and tested
negative for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Prior to
experimental infection, the pigs tested negative for presence of PCV2 in peripheral blood
by real time quantitative PCR (qPCR) and had a sample/positive ratio (S/P) lower than
0.4 for IgM and 0.3 for passive IgG, the PCV2-specific antibodies [4]. Following
infection, experimental pigs were examined daily for clinical signs of disease; weights
and blood samples were collected at 0, 7, 14, 21 and 28 days post infection (dpi). Details
of the experimental procedures, phenotypic and sample collection are described in Engle
et al. (2014) and McKnite et al. (2014).
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A validation dataset consisting of a group of 71 maternal crossbred pigs

representing all three ALGA0110477 genotypes infected with the same PCV2b strain at 5
weeks of age was generated using the same experimental conditions. A group of 40 pigs
(CT and TT genotypes) vaccinated for PCV2 at 3 weeks of age were used as controls.
The vaccinated pigs were housed in the same room with the experimentally infected pigs,
but in different pens.

PCV2b Isolate and Experimental Infection
The PCV2b strain (UNL2014001) used for the experimental infection was
obtained from a pig with symptoms characteristic to PMWS, the most common PCVAD
syndrome. The strain was sequenced (accession KP016747.1) using dye terminators and
compared to PCV2 strains available in GenBank [5]. The strain was cultured in swine
testicular cell lines as described [4]. At an average of 36 days all the pigs were inoculated
with the UNL2014001 PCV2b strain with a titer of 104.0 50% tissue culture infection dose
(TCID50) intranasally and intramuscularly.

Serologic Profile: Quantification of Viral DNA and PCV2-specific Antibodies
PCV2 specific antibodies, IgM and IgG, were profiled weekly from serum using
ELISA (Ingenasa) as described in McKnite et al. (2014). Estimates of the number of
PCV2b copies, or viremia, was performed using viral genomic DNA isolated by QIAamp
DNA Minikit (Qiagen) and quantified by qPCR using TaqMan Master Mix and ABI
7900 Real Time PCR System (Thermo Scientific). The viral load for each pig during the
entire challenge was represented as area under the curve (AUC) based on an algorithm

	
  

	
  

	
  
that takes into account viral levels observed at each time point following infection (0, 7,
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14, 21, and 28 dpi) fitting a smooth curve over the 28 days and summing the areas in 0.01
time increments [6].

Host DNA Isolation, Sequencing, Polymorphism Discovery and Genotyping
The DNA was isolated from ear and tail tissue clips using DNeasy or Puregene
blood and tissue kits (Qiagen). The experimental animals were genotyped using either the
first or second generation of the Porcine SNP60 BeadArray (Illumina) that contain
62,183 and 61,565 SNPs, respectively. Only the common SNPs present in both
BeadArray versions (91.6%, 61,177) were mapped on Sscrofa 10.2 porcine reference
genome assembly. The broad position of the unmapped SNPs on the original Sscrofa
10.2, such as ALGA0110477, was predicted by linkage disequilibrium estimates (r2) with
the mapped SNPs using “Linkage disequilibrium” option from GenSel software package
[7]. An additional 7.2% of the previously unmapped SNPs, including ALGA0110477,
were mapped on Sscrofa 11.1. DNA samples and SNP assays with a genotyping call rate
below 80% were excluded from the analyses and a GenCall quality score of 0.40 was
used as a minimum threshold for genotype quality [8], resulting in 56,433 SNPs (Sscrofa
10.2) used in the GWAS.
Targeted DNA sequencing of candidate genes in the SSC12 QTL region and their
2 – 4 kb region upstream of the transcription start sites (TSS) was performed using dye
terminators and ABI PRISM 3100 Genetic Analyzer (Thermo Scientific) on high and low
viremic samples. Discovery and validation of the polymorphisms detected by RNA-seq
was based on alignment of DNA sequences using Sequencher software (Gene Codes).

	
  

	
  

	
  
Potential impact of the polymorphisms located in the proximal promoter on important
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regulatory motifs was evaluated using FIMO (version 4.11.3)[9] and the JASPAR
transcription profile database (version 2016). Genotyping of polymorphisms located in
transcribed regions and proximal promoters of candidate and surrounding genes was
performed by multiplex assays using Sequenom MassARRAY platform and Sequenom
iPLEX chemistry based on the manufacturer protocols (Sequenom, San Diego, CA).

Genome-Wide Association Studies
The proportion of phenotypic variance explained by host genetics for PCV2viremia, PCV2-specific antibodies (IgM and IgG) and average daily gain (ADGi) during
experimental infection was estimated based on Porcine SNP60 BeadArray genotypes
using a BayesB model [10] and GenSel software [7]. The statistical model included litter,
pen and batch as class variables and passive IgG and age at infection as covariates.
Bayesian regression models fit multiple SNPs in genome-wide associations, assuming
that the marker effects result from a mixture of a point mass distribution whereby SNP
have null effects and a distribution of non-zero effects (e.g., normal, heavy tailed).
Bayesian analyses were based on 𝜋 equal to 0.99 that assumed a prior probability of 1%
of the SNPs having a non-zero effect. Prior assumptions are made relative to the genetic
and environmental variances and the proportion of markers that have a null effect on a
specific trait of interest. These models are implemented via a Markov chain Monte Carlo
(MCMC) sampling algorithm. The posterior means are averaged over the number of
samples from the MCMC [11]. The Markov chain included 40,000 samples with the first
1,000 being removed as burn-in. Markov chain was set to use every 40th sample to

	
  

	
  

	
  
estimate posterior distribution for the genetic variance explained by each 1 Mb window
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of the reference genome. This distribution was used to estimate the probabilities of each
1Mb window having a variance greater than 0 or greater than the average variance
explained by each 1Mb window as described in McKnite et al. (2014).
Bayes Interval Mapping (BayesIM) was implemented to derive haplotype effects
across the genome on PCVAD-related traits as described in Kachman (2015) [12].
Briefly, a hidden Markov model was used to generate 8 haplotype states based on SNP
genotypes [13]. Phenotypic variation of the targeted traits was analyzed with a hierarchal
Bayesian model. QTL were placed every 50 kb across the genome while average
haplotype size was set to 500 kb. Genetic variances, haplotype effects, and model
frequencies were estimated at each locus. There were 42,000 MCMC samples collected
with the first 2,000 used for burn-in. The model included batch, litter and pen as random
effects and IgG and age at infection as covariates. If a locus had an effect, haplotype
effects for each cluster were modeled as independent normal random variables.
Associations between the single marker genotypes and phenotypic variation were
tested using a linear mixed model fitted by JMP 10.0 (SAS Inst. Inc.) that included
marker genotype and batch as fixed effects, litter and pen as random effects while age at
infection and IgG were used as covariates. Additive and dominance effects were
estimated for each of the targeted DNA polymorphisms. A similar model was used to
estimate the interaction between SNPs.

	
  

	
  

	
  
Novel Assembly of the Proximal End of SSC12
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Inverse PCR (iPCR), using four (AciI, AluI, HaeIII, HpaII, RsaII) and six cutter
(EcoRI, HaeII, HincII, HindIII, KpnI, MfeI, MspA1l) restriction enzymes (New England
Biolabs), T4 DNA ligase (New England Biolabs) and nested PCR using AmpliTaq Gold
360 DNA polymerase (Thermo Scientific), was employed to expand the genomic DNA
sequence surrounding the short ALGA0110477 sequence. A genomic scaffold (19 Mb) of
the proximal end of SSC12 was constructed based on Pacific Biosciences sequencing
reads [14]. The position of the extended ALGA0110477 sequence and all SSC12 mapped
and unmapped SNPs were determined on the genomic scaffold using BLAT. Annotation
of the QTL region on the SSC12 scaffold was based on RNA-seq alignments and
BLAST, but also Ab initio approaches such as GenScan [15, 16] in combination with
pBLAST.

RNA-seq and Gene Expression Profiling
In order to profile transcriptome changes and sequence variation related to PCV2
infection, peripheral blood samples collected from the validation group of pigs that
exhibited high (NTT=6) and low (NCC=5) viremic genotypes for ALGA0110477 at 0, 7,
and 14 dpi were subjected to RNA sequencing. RNA was extracted from peripheral blood
collected in Tempus tubes using the Tempus Spin RNA Isolation Reagent Kit (Thermo
Scientific). RNA samples were sequenced using Ion Proton technology as described in
the manufacturer protocol (Thermo Fisher Scientific Inc.). The adaptor-free sequencing
reads were trimmed and filtered using Trim galore (version 0.4) [17] with low-quality
bases in the 5’ end being removed and nucleotides with quality call less than 22 being

	
  

	
  

	
  
trimmed from the 3’ end. The filtered reads were initially aligned to the SSC12 scaffold
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(19 Mb) using the two-step alignment approach used for Ion Proton transcriptome data
that includes both Tophat and local-Bowtie [18]. The reads were later also aligned to the
new pig assembly Sscrofa 11.1. The number of reads mapped to each gene in the
annotated QTL region was obtained using HTSeq (version 0.6.1p1)[19].
Expression of the candidate genes across time points following PCV2 infection
was quantified using TaqMan Master Mix and CFX384 Real Time PCR. The qPCR
assays were designed using IDT Realtime PCR Tool software (www.idt.com) and
sequences generated based on RNA-seq alignments. RNA was extracted from peripheral
blood samples collected in Tempus tubes from a subset of pigs representing all genotypes
from the validation data set that displayed extreme viral load (n=40) from 0 to 21 dpi
using the Tempus Spin RNA Isolation Reagent Kit (Thermo Scientific). Complementary
DNA (cDNA) was obtained using a mix of random hexamers and poly dT primers using
First Strand cDNA Synthesis Kit (GE Healthcare Bio-Sciences). Expression of ribosomal
protein L32 (Rpl32) gene was used for normalization. Mean normalized expression
(MNE) values were calculated based on cycle crossing thresholds (CT) obtained for the
technical triplicates taking qPCR efficiencies into account [20]. MNE values for SYNGR2
p.Arg63Cys and BIRC5 g.-343delA genotypes and time points following infection were
log10 transformed and compared by t-test.
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2.3 Results and Discussion
Two Genomic Loci Influence Host Genetic Effect on PCV2 Infection
As specified in Engle et al. (2014), this study looked at multiple key phenotypes
including weekly viremia and PCV2-specific antibodies, overall viral load, and growth
rate as measures of PCV2 infection. During early infection, the proportion of phenotypic
variation explained by SNP genotypes was low, however, increased following the
observed surge in viremia and associated immune response. For example, proportion of
phenotypic variation accounted for by the SNP genotypes went from 19% at 7 days post
infection (dpi) to 52% at 14 dpi for viremia and from 14% and 3% at 7 dpi to 60% and
44% at 21 dpi for PCV2-specific IgM and IgG respectively (Table 1). However, the
largest proportion of phenotypic variation explained by SNP genotypes was 64% for
PCV2 viral load calculated across time points. Contrarily, the contribution of SNP
genotypes to variation in Average Daily Gain (ADG, monitoring growth rate through
body weight) remained low across time points throughout the challenge, 13% at 7dpi to
7% at 21 dpi, as well as for overall ADG, 16% (Table 1).
The initial GWAS association was performed using a BayesB model where
individual SNPs and successive 1 Mb windows of the genome were evaluated for
association with phenotypic variation [4]. Genome-wide average posterior distribution for
the genetic variance was used to estimate the probability of each 1 Mb window having
greater than the average genetic variance explained across PCV2-related traits. The
GWAS revealed two windows with effects greater than the average effect associated with
both viremia and antibody phenotypes (Pr>0.90) and therefore assumed to represent
“true” Quantitative Trait Loci (QTL) (Figure 1). One QTL was located on SSC7 near the

	
  

	
  

	
  
Swine Leukocyte Antigen Complex Class II (SLAII) at 28-29 Mb and the other was
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putatively located near the proximal end of SSC12, at approximately 3-4 Mb. The top
SNPs (ALGA0039682 and ALGA0110477) associated with the largest genetic variance
for each window both explained over 94% of the genetic variance accounted for by the
window.
The SNP, ALGA0110477, was associated with largest effect on PCV2 viral load,
explaining 11.1% of the genetic variance and 7.4% of the phenotypic variance for viral
load (Figure 2). In the 10.2 reference assembly, this SNP was located on an unplaced
scaffold so linkage disequilibrium estimates between ALGA0110477 and all other SNPs
on the Porcine SNP60 BeadArray were used to determine its potential location. SNPs
ALGA0122316, ASGA0089708, and ASGA0090188 had the highest LD estimates
(r2<0.28) suggesting ALGA0110477 is located on the proximal end of SSC12. However,
despite LD these SNPs or any other within the region did not show any association with
viral load in the initial analysis. Using a different Bayesian approach, BayesIM, [12] that
fits haplotypes across the region rather than individual SNPs, we were able to detect an
effect of this region even when excluding ALGA0110477 from the analysis, supporting
the initial identification of this region as a potential QTL for viral load (Figure 3).
Since the unplaced contig containing ALGA0110477 was not annotated and the
available sequence surrounding the SNP only extended 84 bp, inverse PCR (iPCR) was
used to extend the proximal sequence to 1,252 bp. The elongated sequence was then
compared with contigs from an early version of a long read-based genome assembly of a
pig (accession NPJO00000000) [14], which uncovered a 19 Mb scaffold that provided
precise location of ALGA0110477 and context used for identification of candidate genes.
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The recent release of a long read-based improved reference assembly, Sscrofa
11.1 (GenBank accession GCA_000003025), supported more accurate ordering and
placement of markers, including ALGA0110477 (SSC12, 3,673,576 bp), and facilitated
finer analysis into genomic context with surrounding gene annotation. As a result, an
enhanced profiling of the loci associated with PCV2-related phenotypes across time

points was possible in order to distinguish the role of host genetics in innate and adaptive
immunity.
This analysis utilizing Sscrofa 11.1 and a BayesIM approach, identified the same
two locations on SSC7 and SSC12 as having the largest effects on viral load (Figure 4).
In addition, haplotype effects estimated across the proximal end of SSC12 provided
evidence of haplotypes with divergent effects in viral load, with a peak detected at 3.7
Mb (Figure 5). These QTL were also observed for other targeted traits (Figures 6-8). For
viremia at 14 dpi, both QTL had similar effects, however, at 21 and 28 dpi the SSC7 QTL
had a larger effect (Figure 6). An additional QTL on SSC8 that was not observed for
overall viral load, had the largest effect for viremia at 14 dpi (Figure 6). For PCV2specific antibodies, both QTL were associated with IgM variation (Figure 7), indicative
of active infection, starting at 14 dpi and with IgG variation (Figure 8), representing
previous PCV2 exposure or vaccination, starting at 21 dpi. Together these results provide
evidence of two QTL located on SSC7 and SSC12 that represent the effect of host
variation on PCV2 infection and associated immune response.
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The 19 Mb SSC12 scaffold was used to identify genes surrounding the top marker
ALGA0110477. Annotation of this QTL region was achieved by combining Ab initio
gene prediction, pBLAST, and RNA-seq analysis. Thirteen potential genes with an e
value > 7e-64 and a pBLAST score > 200 were identified. Five of these genes were found
to be expressed in RNA-seq data of peripheral blood from pigs subjected to PCV2. These
five genes had functions in cytokine signaling (SOCS3), inhibition of apoptosis and
regulation of cell proliferation (BIRC5), membrane trafficking and transport (SYNGR2),
and transmembrane ion channels (TMC6 and TMC8).
RNA-seq analysis of alternate ALGA0110477 homozygotes with extreme high
and low viral loads (n=22) were used for initial polymorphism discovery and uncovered 4
missense, 11 synonymous, and 10 UTR SNPs as well as 1 UTR indel across the five
candidate genes. These polymorphisms were confirmed by targeted dideoxy sequencing
of the genes. In addition, sequencing 1-2kb upstream of the Transcription Start Site (TSS)
of BIRC5, SOCS3, and SYNGR2 identified 32 SNPs and 4 short indels. These novel
polymorphisms and 580 SNPs on the Porcine SNP60 BeadArray were mapped to the
scaffold using BLAT. ALGA0110477 had the highest LD with another marker from the
BeadArray (ASGA0086395, r2=0.55) located about 24.5kb away followed by three SNPs
within the SYNGR2 gene (r2= 0.42-0.48) located 123.7kb away.
A subset of samples with extreme high and low viral loads (n=307) were
genotyped for all novel polymorphisms. These genotypes and the Porcine SNP60
BeadArray SNPs that were mapped to the scaffold (n=632) were included in an additive
linear mixed model analysis, which found a missense SNP (p.Arg63Cys) in SYNGR2 and
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a 1 bp insertion (g.-343delA) located 343 bp upstream of the BIRC5 TSS have the largest
effects on PCV2 viral load (Figure 9, F-ratio >47, P<0.0001). In addition, the phenotypic
variance explained by each of the novel mutations was substantially larger (21-23% +/6.1-6.4%) compared to ALGA0110477 (12.6 +/- 4.8%). These polymorphisms were also
associated with large effects on all weekly viremia measures (P<0.0001) and PCV2specific antibodies, starting from 14 dpi for IgM and 21 dpi for IgG (P<0.0001). The
effects on growth during the challenge were most evident after 14 dpi as well as during
the entire challenge period (0 – 28 dpi, P<0.0005).

SYNGR2 and BIRC5 are Potential Candidate Genes Influencing PCV2 Replication
The SYNGR2 p.Arg63Cys SNP is located in the first loop of the SYNGR2 protein
in a region conserved across mammals [21] known to be crucial for formation of
microvesicle membrane fraction [22]. The Arg residue is prevalent in other species (e.g.,
human, rat, cow, horse) sometimes being replaced by His (Rhesus macaque, dog), Lys
(prairie vole, Chinese hamster) or Gln (mouse, golden hamster) while the Cys residue
appears to be specific to swine (Figure 10). The substitution of Arg to Cys determines a
change in charge and hydrophobicity of the loop (Figure 11). The SYNGR2 p.63Cys allele
is favorable with the viral load of the homozygous genotype (Least Square Mean = 54.3
units) being lower compared to the heterozygote (67.03 units, P = 0.005) and alternate
homozygote (p.63Arg, 79.54 units, P < 0.0001). The favorable homozygous genotype
was also associated with lower weekly viremia (P < 0.0001, Figure 12), IgM (> 14 dpi, P
< 0.0001, Figure 13), IgG (> 21 dpi, P < 0.0001, Figure 14) and higher growth (overall 0
– 28 ADG and > 14 dpi, P < 0.001) compared to the alternate homozygote. Expression of
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SYNGR2 did not differ across SYNGR2 p.Arg63Cys genotypes or time points following in
vivo PCV2 challenge.
The 1bp deletion located 343 bp upstream of the TSS of BIRC5 (BIRC5 g.343delA) was found to be in high LD (r2 = 0.83) with SYNGR2 p.63Cys allele and as
expected was associated with low viral load (P < 0.0001). The deletion was predicted to
affect a potential motif for NR5A2, a DNA-binding zinc finger transcription factor.
However, no significant difference in expression was observed between BIRC5
genotypes across time points following in vivo PCV2 challenge (P > 0.17). At 14 dpi the
homozygotes for the insertion exhibited an elevated nominal expression compared to the
other genotypes, but the difference was not significant (P =0.061).
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2.4 Conclusion
In this study, host genotypes explained a substantial proportion of the phenotypic
variation for PCV2 viremia, viral load, and immune response, with two major QTL
identified on SSC7 and SSC12. The inability to uncover a QTL located on SSC12 in the
previous report [4] was based on 1) a genetic structure with a very limited number of
homozygotes for the SYNGR2 p.63Cys allele (Q = 1.2%) in the initial study compared to
the Engle et al. (2014) dataset (Q = 18.3%), which is less favorable for detecting
associations in additive statistical models, and 2) lower ability of ALGA0110477 to
capture the low viremic effects of SYNGR2 p.63Cys. While in the Engle et al. (2014)
dataset the presence of the ALGA0110477 C variant had a 65% probability of being
located on the same haplotype with the SYNGR2 p.63Cys allele, in McKnite et al. (2014)
this variant is found in similar proportions in haplotypes that carry different SYNGR2
alleles (e.g. SYNGR2 p.63Cys; P = 55.9%).
Dissection of the SSC12 QTL based on gene annotation, genomic and RNA
sequencing uncovered a non-conservative substitution in a key domain of the SYNGR2
gene and a single base pair insertion upstream of the BIRC5 gene associated with PCV2
viremia and immune response. Located 41.9 kb apart, the high LD observed between
SYNGR2 p.Arg63Cys and BIRC5 g.-343delA (r2 = 0.83) hampered the ability to
distinguish their individual effects in the in vivo challenge dataset. In contrast, the LD
between SYNGR2 p.Arg63Cys and other SYNGR2 SNPs was limited (r2 < 0.26), as well
as that with BIRC5 g.-343delA and other BIRC5 polymorphisms (r2 < 0.16). Since there
was no significant change in BIRC5 expression throughout the challenge period, we
hypothesize that the missense SYNGR2 p.Arg63Cys mutation is the functional mutation

	
  

	
  

	
  
associated with PCV2 replication and not BIRC5 g.-343delA. We believe that the
observed effect of BIRC5 g.-343delA on PCV2 viral load is due to the tight linkage of
this polymorphism with SYNGR2 p.Arg63Cys. Additionally, we propose that the effects
on growth and PCV2-specific antibodies are a result of the variation in viremia
modulated by SYNGR2.
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CHAPTER 3
SYNAPTOGYRIN-2 INFLUENCES IN VITRO PCV2 REPLICATION IN
PORCINE KIDNEY 15 CELL LINE*

*Parts of this chapter were submitted to PLOS Genetics (2018)
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3.1 Introduction
Synaptogyrin-2 (SYNGR2) is a non-neural member of the synaptogyrin family, a
group of genes primarily expressed in the membrane of synaptic vesicles of neuronal
cells with roles in vesicle biogenesis, exocytosis and recycling via endocytosis [1, 2].
There is limited information about the functional role of this member of the gene family.
Recently, SYNGR2 was implicated as an active player in promoting viral RNA replication
and immune evasion of thrombocytopenia syndrome virus (SFTSV), a novel tick-borne
bunyavirus in humans [3]. SYNGR2 interacted with non-structural viral proteins to
promote the formation of lipid–based inclusion bodies, which become virus factories
within the cytoplasm of infected cells. SYNGR2 mRNA had been upregulated more than
200-fold at 36 hours post infection (hpi) with SFTSV. In vitro silencing of SYNGR2
resulted in a decrease in viral replication and a reduction in the number and size of the
inclusion bodies, further substantiating the role of SYNGR2 in facilitating SFTSV
infection [3].
Following PCV2 uptake, virus-like particles (VLP) were found to be integrated
into intracytoplasmic inclusion bodies in infected cells, in both in vivo and in vitro
experiments [4-6]. The VLP are localized in endosomes at the initial phase of infection.
After release from early endosomes, the viral capsid of PCV2 has been shown to induce
acetylation of microtubular α-tubulin interacting directly with dynein, a molecular motor
used to transport VLP cargo along microtubules to the nucleus for replication [7]. PCV2
is a DNA virus and replication of the viral DNA takes place in the nucleus [8]. As a
result, the involvement of SYNGR2 in endocytosis indicates its potential role in
modulating PCV2 replication and disease progression. SYNGR2 p.Arg63Cys, the only

	
  

	
  

	
  
missense polymorphism identified in SYNGR2 (Chapter 2) and characterized by a
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predicted change in charge and hydrophobicity of the first loop that connects two
essential transmembrane domains, is located in a region conserved across mammals
(Chapter 2). In rats, the first intraluminal loop and C-terminus of SYNGR2 were found to
be crucial for successful incorporation of the protein into vesicular membranes and
vesicle formation [1]. Replacement of residues 67–73 in the first loop led to protein
degradation, with residues 70–73 having the largest impact [1]. In pigs, this segment of
four residues is analogous to amino acids 60–63.
Considering that the location of the SYNGR2 p.Arg63Cys substitution is in a
conserved domain involved in vesicle formation [1] and recent literature support of
SYNGR2 affecting replication of a tick-borne human RNA virus [3], we hypothesize that
SYNGR2 may play a role in the internalization and early release of PCV2 from
endosomes influencing efficient trafficking of VLP to the nucleus for replication. In order
to validate a role of SYNGR2 in facilitating PCV2 replication, we transfected Porcine
kidney 15 cell line (PK15) with small interfering RNAs (siRNA) targeting the mRNA of
SYNGR2 and subsequently inoculated the silenced cells with the same PCV2b isolate
used in vivo (UNL2014001).
The PK15 cell line has an epithelial origin and is a well-established model system
for PCV2 innate immunity and cellular pathogenesis [9]. The purpose of transfecting the
cells with SYNGR2-specific siRNA was to silence or suppress the expression of SYNGR2
by utilizing a natural process known as RNA interference [10]. The siRNA are 21 to 23
nucleotides long with sequence specificity for certain mRNA. Once integrated into the
cell, these siRNA assemble with proteins forming an endonuclease complex and act as

	
  

	
  

	
  
guide RNAs targeting complementary mRNA for degradation [10]. Thus, siRNA
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modulate gene expression by degrading mRNA prior to translation, preventing generation
of proteins. However, exogenous delivery without endogenous expression of the desired
siRNA results in transient suppression lasting about a week in vitro [10]. By silencing
SYNGR2, we could provide evidence of its role in PCV2 infection and impact on viral
replication.
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3.2 Materials and Methods
PK15 Cell Culture, Sample Collection, and Genotyping
The porcine kidney cell line (PK15), was grown in DMEM high glucose media
supplemented with 10% FBS and 1% Penicillin-Streptomycin (5,000 U/mL). Cell
samples were collected from culture plates in PBS and centrifuged for ~1 min at
16,000xg to pellet the cells. PBS was removed and pelleted cells were stored at -80°C.
DNA and RNA were extracted using TRIzol reagent following the manufacturers
protocol (Thermo Fisher). The cDNA was generated from extracted RNA using First
strand cDNA Synthesis Kit (GE Healthcare Bio-Sciences). Dideoxy sequencing of the
cDNA and genomic DNA was used to profile the gene sequences and genotype the
BIRC5 and SYNGR2 variants in the PK15 cell line.

In vitro PCV2 Infection of PK15 Cells and Expression Profiling
Cells were cultured in 12-well plates (4 cm2) with 5.0x105 cells per well and
infected with UNL2014001 PCV2b strain (TCID50=104) when 80-100% confluent at
MOI=0.00025. One hour following infection, cells were washed and fresh media was
added (DMEM high glucose and 2% FBS). The cells were incubated at 37 ◦C with 5%
CO2 for up to 5 days. Control cells were maintained the same way and mock inoculated
with plain DMEM high glucose media. Supernatant and cells were collected at specific
time points (0, 12, 24, 48, 72, and 96 hpi) and frozen at −80 ◦C. Viral DNA was extracted
from supernatant using QIAamp DNA Mini kit (Qiagen). RNA, viral and host DNA was
extracted from PK15 cells using AllPrep DNA/RNA Mini kit (Qiagen). TaqMan Master
Mix and CFX384 Real Time PCR Detection System (BioRad) were used for
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quantification of PCV2 and expression profiling of BIRC5 and SYNGR2 from PK15 cells.
Expression of ribosomal protein L32 (Rpl32) gene was used for normalization of gene
expression. MNE values of SYNGR2 and BIRC5 were log10 transformed and compared
by t-test between control and infected cells.

In vitro Silencing of SYNGR2 in PK15 Cells
PK15 cells were transfected 24 hours after plating in 12-well plates (4 cm2) with
2.5x105 cells per well when ~80% confluent with two siRNA oligos targeting SYNGR2
mRNA (siRNA-01: sense 5’-CUACAAGGCCGGAGUGGAUUU-3’, and antisense 5’AUCCACUCCGGCCUUGUAGUU-3’;

siRNA-03: sense 5’-CCACAAGUCCGGAGAGCAGUU-

3’, and antisense, 5'-CUGCUCUCCGGACUUGUGGUU-3', Dharmacon Research) and the
AllStars Negative Control siRNA (scramble, Qiagen) at 10nM and 20nM concentrations.
Transfection was performed using Lipofectamine RNAiMAX transfection reagent
(Invitrogen) following the manufacturer’s protocol. Cell samples were collected 24, 48,
72, and 96 hours post transfection and stored at -80◦C. RNA was extracted using
RNAeasy Mini kit (Qiagen). Real Time PCR was used to profile SYNGR2 expression.
Following initial testing, the siRNA-01 and AllStars Negative Control siRNA both at
20nM concentrations were used for subsequent transfections. Cells were inoculated 24
hours after transfection following the same infection protocol described above. Statistical
differences in viral titer between cell lines across time points were tested using a linear
model fitted by JMP 10.0 (SAS Inst. Inc.) that included batch and cell line as fixed
effects. Pairwise comparisons between least-squares means of the viral titers were based
on the Tukey test.
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3.3 Results and Discussion
BIRC5 and SYNGR2 Gene Structure and Variants in PK15 Cells
Targeted cDNA and genomic DNA sequencing of the PK15 cell line for both
genes revealed no differences in transcript structure compared to the RNAseq data for
either SYNGR2 or BIRC5. Interestingly, only one BIRC5 isoform was observed in the
PK15 cell line compared to four isoforms present in the RNAseq data from pig sera
collected during the experimental challenge. The isoform includes 4 complete exons and
was the predominate isoform observed in vivo. The PK15 cell line was also determined to
be homozygous for the unfavorable alleles associated with increased viral load for both
SYNGR2 p.Arg63Cys (p.63Arg) and BIRC5 g.-343delA (g.-343insA).

In vitro PCV2 Infection had No Effect on Expression of BIRC5 or SYNGR2
Successful infection of PK15 cell culture with PCV2b inoculate was observed,
with consistent infection profiles across three independent replications in both
supernatant and cell samples (Figures 15 and 16). In the supernatant we saw an increase
in viral copies from 0 to 12 and 24 to 72 hpi, with plateaus observed from 12 to 24 hpi
and at 96 hpi (Figure 16). In the cell samples we observed a decrease in viral copies per
well between 0 and 12 hpi, which is expected because at 0 hours the cells are saturated
with PCV2 virions, however, only a portion of the virions will successfully enter the cell
and able to be observed at 12 hpi (Figure 15). The rest of the virions will be released and
present in the supernatant. From 12 hours onward we see a consistent increase in PCV2
copies, indicating successful PCV2 replication and proliferation, with PCV2 titer peaking
at 72 hpi and decreasing slightly at 96 hpi likely due to cell loss (Figure 15).
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Expression profiling of BIRC5 and SYNGR2 across time points post infection
showed no significant difference in expression for either gene between infected and
control cells, corroborating in vivo findings. Although expression of SYNGR2 increased
and BIRC5 decreased over the 4-day period following infection, these changes were
observed in both infected and control cells (Figures 17 and 18). The lack of evidence to
suggest that PCV2 infection triggers changes in gene expression strengthened our

hypothesis that SYNGR2 p.Arg63Cys is the functional source responsible for variation in
PCV2 replication.

Viral titer was Decreased in SYNGR2-Silenced Cells Infected with PCV2
We evaluated two siRNA (siRNA-01 and siRNA-03) at two different
concentrations (10 nM and 20 nM) and found that siRNA-01 was the most efficient to
knockdown mRNA level of SYNGR2 compared to the cells subjected to a scramble
siRNA control, with an average reduction of 82.2% in SYNGR2 mRNA level observed
starting 24 hours after transfection (≈0 hpi, Figure 19). PK15 cells with the expression of
SYNGR2 silenced were then infected with PCV2 24 hours after transfection. A reduction
in viral titer was observed in the SYNGR2 silenced cells subjected to PCV2 starting at 48
hpi when compared to scramble siRNA and non-transfected control cells, indicating a
role of SYNGR2 in viral replication (P <0.05, Figure 20). The viral titer across time points
was not statistically different between the scramble siRNA and non-transfected control
cells (P > 0.54, Figure 20).
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3.4 Conclusion
In our study, we observed similar results to those reported by Sun et al. (2016), in
that silencing of SYNGR2 expression in PK15 cells was associated with a significant
reduction in PCV2 titer, indicating a role of SYNGR2 in promoting viral replication.
Although, we did not observe an increase in SYNGR2 mRNA levels following in vitro
(like in Sun et al. study) or in vivo infection with PCV2, this may simply reflect important
distinctions between SFTSV and PCV2. For instance, SFTSV is an RNA virus with the
capacity to replicate within intracytoplasmic inclusion bodies, or viral factories. As Sun
et al. (2016) illustrated, SYNGR2 is a component of these vesicles and necessary for their
formation. As SFTSV replicates, more viral factories will be required for viral
proliferation, resulting in increased levels of SYNGR2. PCV2, on the other hand, is a
DNA virus and can only replicate in the nucleus of host cells. Therefore, the potential
role of SYNGR2 in PCV2 infection likely takes place prior to viral replication and may
not require such an increase in SYNGR2 expression, but rather specific SYNGR2-PCV2
interactions. Since the position of this substitution is clearly located in a loop domain and
not part of a transmembrane region as indicated by Janz and Sudhof (1998) and predicted
by PSIPRED [11], an interaction between SYNGR2 and a ligand is favored compared to
the potential impact of SYNGR2 p.Arg63Cys on overall protein folding or loop
conformation (Figures 21 and 22). Therefore, as long as there is an adequate level of
SYNGR2 protein, efficient PCV2 infection is possible.
While further research is required to define the mechanism in which SYNGR2 and
its alleles alter PCV2 multiplication, we propose the following theories based on current
findings and the nature of PCV2 infection. We hypothesize that the interaction between a

	
  

	
  

	
  
ligand and the protein encoded by the SYNGR2 p.63Cys allele may 1) reduce the ability
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of the virus to enter the cell through the endocytic pathway or be internalized into
endosomes following cellular entry, 2) alter capsid release from early endosomes, thus
preventing migration of the virus to the nucleus for DNA replication or 3) decrease the
efficiency of virus uncoating, an essential step required for successful replication.
Additional studies utilizing gene editing technology will also be necessary to provide
direct experimental evidence of the impact of allelic substitution at the SYNGR2
p.Arg63Cys locus on PCV2 replication, however, based on our data we believe the
SYNGR2 p.Cys63 variant decreases the ability of PCV2 to replicate following infection.
The significant decrease in viral titer observed following an 80% reduction in SYNGR2
expression in vitro, despite presence of the unfavorable BIRC5 variant, provides strong
evidence of the involvement of SYNGR2 in PCV2 infection. Together with the lack of
expression differences for BIRC5 in vivo and in vitro in response to PCV2 infection,
strongly suggests the only missense mutation, SYNGR2 p.Arg63Cys, to be a plausible
quantitative trait nucleotide (QTN) for PCV2 susceptibility. These findings not only
contribute to a better understanding of the critical players involved in pathogenesis of
PCV2 infected cells, but also the role of host genetics in viral disease susceptibility.
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TABLES

Table 1. Proportion of phenotypic variance explained by SNPs from Porcine SNP60
BeadArray using Bayes B of PCV2-related traits days post infection (dpi) with
PCV2.
	
  

	
  

Trait/dpi

7

14

21

28

0-28

Viremia

0.19

0.52

0.45

0.39

0.64

IgM

0.14

0.60

0.44

0.52

IgG

0.03

0.08

0.44

0.38

Trait/dpi

0-7

7-14

14-21

21-28

0-28

ADG

0.13

0.11

0.07

0.07

0.16
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FIGURES

Figure 1. Probability of a 1 Mb window to have an effect above the average effect of
the genome-wide 1 Mb windows estimated using BayesB on overall Average Daily
Gain (ADG) and PCV2 viral load (AUC). The genetic variance for PCV2 viral load
explained by the top two 1 Mb windows that included ALGA0039682 (SSC7) and
ALGA0110477 (SSC12) have effects above the 1 Mb window average effect (P > 0.90).
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Figure 2. Genome-wide association between 56,433 SNPs and PCV2b viral load
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using BayesB. Each dot represents the proportion of genetic variance explained by an
individual SNP. The x-axis represents the position of each SNP in the swine genome
using Sscrofa 10.2 assembly. The y-axis represents the contribution of each SNP to the
genetic variance. Alternate colors represent autosomes, from SSCs 1 to 18, chromosome
X and Y followed by a set of SNPs without a genomic location. ALGA0110477 is located
in the last group of SNPs with the genomic location unassigned, but characterized by a
model frequency of 0.96.
	
  

	
  

	
  

	
  
Figure 3. Genome-wide association between 54,946 SNPs and PCV2b viral load
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using BayesIM. Marker ALGA0110477 and all other unmapped SNPs were excluded
from the analysis. Each dot represents the model frequency associated with each 50kb
QTL. The X-axis represents the position of the QTL across the swine genome using
Sscrofa 10.2 assembly. The Y-axis represents the model frequency of the association
between a QTL and PCV2 viral load. Alternate colors represent autosomes, from SSC1 to
18.
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Figure 4. Genome-wide association between 51,592 SNPs and PCV2b viral load
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using BayesIM. Each dot represents the model frequency associated with each 50kb
QTL. The X-axis represents the position of the QTL across the swine genome using
Sscrofa 11.1 assembly. The Y-axis represents the model frequency of the association
between a QTL and PCV2 viral load. Alternate colors represent autosomes, from SSC1 to
18.
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Figure 5. Haplotype effects for PCV2 viral load across the proximal end of SSC12
estimated using BayesIM model.
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Figure 6. Genome-wide association between 51,592 SNPs and PCV2b viremia using
BayesIM. Each dot represents the model frequency associated with each 50kb QTL. The
X-axis represents the position of the QTL across the swine genome using Sscrofa 11.1
assembly. The Y-axis represents the model frequency of the association between a QTL
and PCV2 viremia. Alternate colors represent autosomes, from SSC1 to 18.

	
  

	
  

	
  
Figure 7. Genome-wide association between 51,592 SNPs and PCV2-specific IgM
using BayesIM. Each dot represents the model frequency associated with each 50kb
QTL. The X-axis represents the position of the QTL across the swine genome using
Sscrofa 11.1 assembly. The Y-axis represents the model frequency of the association
between a QTL and IgM following PCV2 infection. Alternate colors represent
autosomes, from SSC1 to 18.
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Figure 8. Genome-wide association between 51,592 SNPs and PCV2-specific IgG
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using BayesIM. Each dot represents the model frequency associated with each 50kb
QTL. The X-axis represents the position of the QTL across the swine genome using
Sscrofa 11.1 assembly. The Y-axis represents the model frequency of the association
between a QTL and IgG following PCV2 infection. Alternate colors represent autosomes,
from SSC1 to 18.
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Figure 9. Association results between the genotypes of the DNA polymorphisms
mapped to the 19 Mb scaffold of the proximal end of SSC12 and PCV2 viral load

using a linear mixed additive model. The line represents a smoother with a default λ of
0.05. SYNGR2 p.Arg63Cys and BIRC5 g.-343delA were associated with the largest
effects on PCV2 viral load (F-ratio > 47, P < 0.0001).
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Figure 10. Sequence alignment of the first loop of SYNGR2 across mammalian
species. The red block indicates a conserved region demonstrated to be important in
successful incorporation of the protein into vesicular membranes and vesicle formation.

	
  

	
  

94

	
  
Figure 11. Hydrophobicity profile of the SYNGR2 Arg63Cys polypeptides based on
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the Kyte and Doolittle scale (the window consisted of 9 amino acid residues). An
increase in the hydrophobicity score was observed in the predicted SYNGR2 p.63Cys
polypeptide.
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Figure 12. Least square means (LSM) and standard errors of the SYNGR2
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p.Arg63Cys genotypes (63Cys/63Cys - green, 63Arg/63Cys - red, 63Arg/63Arg - blue)
across weekly viremia measures following PCV2 challenge (n=307).
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Figure 13. Least square means (LSM) and standard errors of the SYNGR2
p.Arg63Cys genotypes (63Cys/63Cys -green, 63Arg/63Cys-red, 63Arg/63Arg-blue)
across weekly IgM PCV2-specific antibody following PCV2 challenge (n=307).
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*Significant difference between alternate homozygotes (P <0.0001)
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Figure 14. Least square means (LSM) and standard errors of the SYNGR2
p.Arg63Cys genotypes (63Cys/63Cys -green, 63Arg/63Cys-red, 63Arg/63Arg-blue)
across weekly IgG PCV2-specific antibody following PCV2 challenge (n=307).
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Figure 15. PCV2 copy number from PK15 cells following inoculation with the
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UNL2014001 PCV2b strain. Number of viral copies is expressed as the mean log10
copies/well for 3 independent replicates with errors bars representing standard error of
the mean.
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Figure 16. PCV2 copy number from supernatant samples following inoculation with
the UNL2014001 PCV2b strain. Number of viral copies is expressed as the mean log10
copies/uL per 200 uL supernatant sample for 3 independent replicates with errors bars
representing standard error of the mean.

	
  
	
  

	
  

	
  

	
  
Figure 17. Expression of SYNGR2 in PK15 infected and control cells following
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inoculation with UNL2014001 PCV2b strain. Expression represented as the mean
log10 MNE across 3 independent replicates with error bars representing standard error of
the mean.

	
  

	
  

	
  
Figure 18. Expression of BIRC5 in PK15 infected and control cells following
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inoculation with UNL2014001 PCV2b strain. Expression represented as the mean
log10 MNE across 3 independent replicates with error bars representing standard error of
the mean.

	
  
	
  

	
  

	
  

	
  
Figure 19. Expression of SYNGR2 in PK15 cells transfected with SYNGR2 specific
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siRNA-01, scramble siRNA, and non-transfected controls following inoculation with
UNL2014001 PCV2b strain. Expression represented as mean log10 MNE relative to
controls across 3 independent replicates with error bars representing standard error of the
mean.
	
  

	
  
	
  

	
  

	
  

	
  
Figure 20. PCV2 copy number from PK15 cells transfected with SYNGR2 specific
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siRNA-01, Scramble siRNA, and non-transfected controls following inoculation with
UNL2014001 PCV2b strain. Number of viral copies from PK15 cells is expressed as
mean log10 copies/well across 3 independent replicates with error bars representing
standard error of the mean.
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Figure 21. Secondary structure of SYNGR2 p.63Cys allele predicted by PSIPRED
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Figure 22. Secondary structure of SYNGR2 p.63Arg allele predicted by PSIPRED
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